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The molecular details of antigen processing and 
presentation by MHC class II molecules have been 
studied extensively for almost three decades. 
Although the basics of these processes were laid out 
some ten years ago, the recent years have revealed 
many details and provided new insights into their 
control and specificity. MHC molecules employ 
various biochemical reactions in order to achieve 
successful presentation of antigenic fragments 
to the immune system. Here we present a timely 
evaluation of the biology of antigen presentation 
and a survey of issues considered unresolved. The 
continuing flow of new details into the biology of 
MHC class II antigen presentation is exciting and 
builds a system involving several cell biological 
processes, which is being discussed in this chapter.
Introduction
Major Histocompatibility class I and II molecules 
(MHC-I and MHC-II) are similar in function: they 
present peptides at the cell surface to CD8+ and 
CD4+ T cells, respectively. These peptides originate 
from different sources - intracellular for MHC-I 
and exogenous for MHC-II - and are obtained 
via different pathways [1]. An interesting link, 
termed cross-presentation, exists between the 
two pathways, whereby exogenous antigens are 
presented by MHC-I [2]. In addition, cytosolic 
proteins can be presented by MHC-II when proteins 
are degraded through the autophagy or other 
pathways [3]. Furthermore, the various mechanisms 
that pathogens have evolved to manipulate the 
MHC-I and MHC-II pathways have provided new 
insights into the biology of antigen presentation [4]; 
however, we will not further discuss these topics, as 
they have recently been reviewed [2-4].
MHC-II: like and unlike MHC-I Molecules
MHC-I and MHC-II molecules overlap in a number 
of characteristics: high polymorphism, similar 3D 
structure due to the fact that they originate from one 
common founder gene by simple gene duplication, 
location in one gene locus and presentation of 
peptides to the immune system. Yet, these molecules 
show a different tissue distribution and differ in the 
types of antigenic peptides presented as a result of 
their different cell biology. 
Like MHC-I, MHC-II is encoded by three polymorphic 
genes (HLA-DR, HLA-DQ and HLA-DP in humans) that 
bind different peptides. Some of the MHC-II alleles 
are known to be the strongest genetic markers 
associated to autoimmune diseases, possibly due to 
the peptides they present [5]. Although the different 
alleles appear to associate differentially with the 
chaperone HLA-DM (see later) [6], the effects of 
MHC-II polymorphism on their cell biology is poorly 
studied when compared to MHC-I. The MHC-II 
pathway described below is mainly based on studies 
of HLA-DR and murine MHC-II (I-A and I-E). Of note, 
the pathway may differ in details for other MHC-II 
molecules.
 
The Basics of MHC-II Antigen Presentation
While MHC-I is ubiquitously expressed, MHC-II 
molecules are primarily expressed by professional 
APCs, such as dendritic cells (DCs), macrophages and 
B cells. It has been concluded from the work of many 
groups that the transmembrane α- and β-chains of 
MHC-II are assembled in the ER and associate with the 
Figure 1 | The Basics MHC Class II Antigen Presentation 
Pathway
MHC-II a- and b-chains assemble in the ER and form 
a complex with the Ii.  The MHC-II/Ii heterotrimer 
is transported through the Golgi to the MIIC, 
either directly and/or via the plasma membrane. 
Endocytosed proteins and the Ii are degraded here by 
resident proteases. The CLIP fragment of Ii remains in 
the peptide-binding groove of MHC-II and is exchanged 
for proper peptide with the help of the dedicated 
chaperone HLA-DM. MHC-II is then transported to 
the plasma membrane for presentation of antigenic 
fragments to CD4+ T cells.
CLIP, Class II associated Invariant chain Peptide. ER, 
Endoplasmic Reticulum. Ii, Invariant chain. MIIC, MHC 
II Compartment. TCR, T-cell receptor. 
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invariant chain (Ii). The resulting MHC-II-Ii complex 
is transported to late endosomal compartments, 
termed MIIC (MHC class II compartment). Here, 
Ii is digested, leaving a residual class II-associated 
Ii peptide (CLIP) in the peptide-binding groove 
of MHC-II. In the MIIC, MHC-II requires HLA-DM 
(H2-DM in mice) to facilitate the exchange of the 
CLIP fragment for a specific peptide derived from 
proteins degraded in the endosomal pathway. MHC-
II is then transported to the plasma membrane to 
present its peptide cargo to CD4+ T cells (Figure 1). 
In B cells, a modifier of HLA-DM is expressed called 
HLA-DO (H2-O in mice) which associates with HLA-
DM and restricts HLA-DM activity to more acidic 
compartments thus modulating peptide binding to 
MHC-II [7]. 
Cross-presentation aside, MHC-I presents peptides 
of cytosolic origin, whereas MHC-II carries peptides 
derived from antigens degraded in the endocytic 
pathway. Their combined specificities cover antigens 
from almost all cellular compartments. However, 
essential differences in the pathways complicate 
this basic paradigm. In addition, various issues are 
less well understood and no numbers to calculate 
the reaction efficiencies leading to MHC-II peptide 
loading have been reported.
The Complexity of MHC-II Antigen 
Presentation
MHC-II Expression
Unlike MHC-I, the expression of MHC-II is restricted 
to APCs. However, MHC-II expression can be 
induced by IFNγ and other stimuli in non-APCs, 
including mesenchymal stromal cells [8], fibroblasts 
and endothelial cells [9], and in epithelial cells and 
enteric glial cells in Crohn’s disease [10, 11] and 
eosinophilic esophagitis [12]. Also dermatoses, such 
as psoriasis [13], can induce MHC-II expression by 
keratinocytes [14]. Non-APCs may express MHC-
II in the absence of co-stimulatory molecules that 
may drive or attenuate local T cell responses. The 
question is, how expression of MHC-II is controlled 
in APC and non-APCs.  
The master regulator of MHC-II expression is class 
II transactivator (CIITA). CIITA is recruited by the 
MHC-II enhanceosome (which contains cyclic-AMP-
responsive-element-binding protein (CREB), nuclear 
transcription factor Y (NFY) and the regulatory 
factor X (RFX) complex) to the X1, X2, Y-box 
elements at the MHC-II locus (reviewed in [15]). CIITA 
expression is regulated in a more complex manner, 
yielding CIITA isoforms I, III and IV [16, 17], which 
are expressed in different cell types. Transcriptional 
regulation of MHC-II in DCs is controlled by an 
additional layer of regulation. In immature DCs, four 
factors (PU.1, IRF8, NF-kB and SP1) bind to the type 
I CIITA promoter resulting in high CIITA transcription 
and, as a result, high MHC-II transcription. During DC 
maturation, this complex is replaced by a complex 
containing PR domain zinc finger protein 1 (PRDM1) 
and B-lymphocyte-induced maturation protein 1 
(BLIMP1) that inhibits CIITA transcription [18] (Figure 
2B). In addition, CIITA requires phosphorylation [19, 
20] and mono-ubiquitination [21, 22] before being 
active as the MHC-II transcription factor in APCs. 
By combining the results of a genome-wide small 
interfering RNA (siRNA) screen with quantitative 
PCR, five upstream regulators of CIITA (CDCA3, 
RMND5B, CNOT1, MAPK1 and PLEKHA4) were 
recently identified. By determining how these factors 
controlled the expression of each other, a complex 
feedback mechanism in control of CIITA and MHC-II 
transcription was uncovered [23 and Chapter 1 of this 
thesis] (Figure 2A). In fact, a complex transcriptional 
feedback mechanism is the only mechanism possible 
to explain how a master regulator of transcription 
(CIITA) is controlled by the next factor that is 
controlled by the next ad infinitum. However, 
the factors constituting the feedback mechanism 
should also be controlled. Further systems biology 
analyses showed that feedback control of CIITA 
expression is determined by the combined activities 
of transforming growth factor b (TGFb) signalling 
and chromatin modifications leading to MHC-II 
transcription in APCs [23]. Tissue specific regulation 
of MHC-II expression is then the consequence of two 
general terms; chromatin modifications that include 
epigenetics, and signalling by external factors. The 
latter has been noticed earlier as a series of cell types 
only express MHC-II under inflammatory conditions 
(see later). In summary, transcription of MHC-II is 
controlled by the master regulator CIITA, which in 
turn is regulated by post-translational modifications 
and factors mainly, but not exclusively, active in 
immune cells. Under defined conditions of signalling 
and chromatin modifications, CIITA and MHC-II can 
be expressed in non-immune cells, often in response 
to infections or inflammation.
 
MHC-II Transport from ER to the MIIC
Although both MHC-I and MHC-II are assembled in 
the ER, MHC-I needs to be loaded with peptide to 
leave the ER, whereas MHC-II associates with Ii [24]. 
Four different splice variants of Ii exist, with variation 
in the cytoplasmic tail (the p33 and p35 variants) or 
inclusion of an additional exon encoding a protease 
inhibitor cystatin (the p43 and p45 variants) [25, 26]. 
While the α and β chain of MHC-II are ER-bound, 
the assembled MHC-II αβ heterodimers is already 
slowly leaving the ER, which is further accelerated 
by Ii binding. It is believed that the CLIP region 
I
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of Ii blocks the peptide-binding groove of MHC-
II, thus preventing binding of other peptides in 
the ER. Indeed, the levels of endogenous antigen 
presentation is higher in Ii knockout mice [27], but 
biochemical analyses of the same mice suggest this 
is not an efficient process, as most MHC-II are not 
converted into a stable peptide-loaded form in the 
absence of Ii [28, 29]. Yet, particular antigens can 
access MHC-II after TAP-dependent translocation in 
the ER [30] but the vast majority of peptides will fail 
Figure 2 | Complexity of the MHC Class II Antigen Presentation Pathway
Insights in the various steps of the MHC-II pathway are shown in different boxes projected on the basic pathway 
of Figure 1. a | MHC-II transcription is controlled by master regulator CIITA ensuring tissue specific expression. 
CIITA is controlled by a feedback loop of factors that are subsequently controlled by two general processes: 
(TGFb) signaling and chromatin modifications. b | CIITA expression is differentially controlled in imDC (via an 
activating transcriptional complex) and mDC (via an inhibitory complex). Consequently, CIITA (with other 
factors) induces transcription of MHC-II in imDC unlike in mDC. c | Adaptor proteins binding the Ii are known. 
AP2 drives internalization of MHCII-Ii complexes via CCV at the plasma membrane for endocytosis and transport 
to the MIIC. d | In the MIIC, Ii is degraded and MHC-II interacts with HLA-DM. Most HLA-DM and MHC-II locate and 
interact in the internal structures formed by the ESCRT machinery. The mechanism of back-fusion of internal 
DM and MHC-II to the limiting membrane is hypothetical. e | MHC-II or its tubular extensions are transported by 
the microtubule-based motor proteins dynein and kinesin. These have receptors on the MIIC, like RAB7-RILP for 
the dynein motor. The final step involves actin-based myosin motors that interact with the MIIC via Ii (MYOII) or 
the GTPase ARL14 (MYO1E). The latter mechanism controls MIIC secretion in imDC. f | In imDCs, internalization of 
MHC-II from the plasma membrane may require the ubiquitin ligase MARCH1 which is controlled by IL10. CD83 on 
mDC prevents this ubiquitin modification of MHC-II which stabilizes MHC-II cell surface expression.
AP2, Adaptor Protein-2. CCV, Clathrin Coated Vesicle. CIITA, Class II TransActivator. imDCs, immature Dendritic 
Cell. mDCs, mature Dendritic Cell. Ii, invariant chain. MHC, Major Histocompatibility Complex. MIIC, MHC II 
Compartment. MTOC, Microtubuli organizing centre. TCR, T-cell receptor.
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to enter MHC-II due to Ii.  
The cytoplasmic tail of Ii contains two classical 
di-leucine sorting motifs that direct MHC-II to 
endosomal compartments (Figure 2C). These sorting 
motifs are recognized by the sorting adaptors 
AP1 (a trans-Golgi network adaptor) and AP2 (a 
plasma membrane adaptor) [31]. Ii may direct MHC-
II directly from the trans-Golgi network to MIIC 
or by endocytosis from the plasma membrane. 
Endocytosis may be preferred in human cervical 
carcinoma cells (HeLa cells) and immature DCs (AP2 
dependent) [32, 33], whereas direct sorting may be 
dominant in mature DC (AP1 dependent) [34]. In 
summary, Ii is essential for various steps in the life 
of MHC-II, but may take different routes to its final 
destination, which is the endosomal pathway where 
Ii is degraded before MHC-II finally acquires its final 
peptide.
The MHC-II Peptide-loading Compartment
While MHC-I binds peptides in a partially folded state 
stabilized by chaperones in the ER, this is probably 
different for MHC-II, as endosomes are not known to 
contribute to folding. The location of MHC-II peptide 
loading has been a matter of debate since the 
MIIC was visualized by electron microscopy in 1990 
[35]. At that time, the MIIC was shown to contain 
MHC-II and Ii, to be multilamellar in morphology, 
to be acidic and to contain lysosomal proteases 
and CD63, which defined it as late endosomal [35]. 
Other structures were subsequently identified and 
a revised definition for the MIIC was required. The 
MHC-II chaperone HLA-DM was found to localize 
in late endosomes [36], where it stabilizes MHC-II 
either bound to or devoid of the CLIP peptide (thus 
preventing aggregation and degradation of MHC-
II) until high affinity peptides bind [37] (Figure 2D). 
The late endosomal tetraspanin proteins [38] which 
interact with HLA-DM and MHC-II, and probably 
induce the formation of a proteinacious network, 
were identified, as were the proteases cathepsin 
S and cathepsin L that degrade Ii [39]. An in vitro 
reconstitution experiment defined the molecules 
minimally required for the MIIC as MHC-II, HLA-DM 
and cathepsins [40] and the combined data suggest 
that a late endosomal structure with (at least) these 
three factors would fulfill the criteria for the MIIC. 
A complicating factor is that the MIIC is not 
homogeneous but exists in multiple morphologies 
(multivesicular, mixed and multilamellar) that may 
represent different maturation states. MHC-II, 
HLA-DM and other molecules are located mainly in 
the internal structures of the MIIC and have to be 
ubiquitinated and sorted by the endosomal sorting 
complex required for transport (ESCRT) machinery 
on the limiting membrane [41]. Fluorescence 
resonance energy transfer (FRET) studies have 
suggested that HLA-DM interacts with MHC-II on the 
internal vesicles of the MIIC and not on the limiting 
membrane [42]. The internal vesicles carrying MHC-
II and HLA-DM are thought to fuse back to the 
limiting membrane of MIIC to prevent secretion in 
the form of exosomes and to be embedded in the 
plasma membrane. This process of ‘retrofusion’ 
has not yet been defined. Another model proposes 
that peptide-loaded MHC-II appearing on the 
plasma membrane in DCs originate from the limiting 
membrane and that MHC-II on internal vesicles are 
destined for degradation [43]. However, as most of 
the MHC-II is found on internal vesicles, a major loss 
of MHC-II would be expected to occur, but this was 
not observed in biochemical experiments [44]. The 
molecular mechanisms of retrofusion (if any) need 
to be defined to explain this contradiction.
Although the intracellular location for peptide 
loading of MHC-II seems to be in the MIIC, many 
issues have yet to be resolved. These include the 
entry of MHC-II via earlier endosomes into the MIIC 
and the functional role of Ii to mediate fusion of early 
endosomes [45] and regulate intracellular transport 
of MHC-II [46]. MHC-II will probably present 
different peptides when sampling these in different 
parts of the endosomal pathway with different help 
of HLA-DM [47]. Finally, degradation of antigens 
is strongly delayed in immature DCs possibly as a 
mechanism to store antigens for presentation over 
long periods of time [48]. Whereas the minimal MIIC 
has been defined, the consequences of different 
MIIC morphology, different proteolytic activities, 
controlled acidification during DC maturation, 
retrofusion and other processes need to be 
defined for a more complete understanding of the 
intracellular process of MHC-II antigen loading.
MHC-II Transport from MIIC towards the 
Plasma Membrane
Late endosomal compartments such as MIIC are not 
typical recycling structures; yet MHC-II, HLA-DM, 
tetraspanins and other molecules are transported 
from the MIIC to the plasma membrane. The content 
of MIIC, including MHC-II, is released after a specific 
time period. This release is controlled by factors such 
as cholesterol, cytosolic pH, kinases and GTPases.
Fast transport of MIIC and other vesicles is driven by 
the microtubule-based motors dynein (for inward 
transport) and the kinesin family (for outward 
transport), whereas slow vesicle transport involves 
the actin-based myosin motor family. Motor proteins 
require vesicle receptors that are subsequently 
controlled by other processes. The molecular basis 
for this part of cell biology is largely undefined with 
few exceptions. Inward transport of MIIC by the 
I
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dynein motor is controlled by the RAB7-interacting 
lysosomal protein (RILP) on MIIC (Figure 2E), which 
is further controlled by the cholesterol-sensor OSBP-
related protein 1L (ORP1L) and the ER-resident 
protein VAMP-associated protein A (VAPA) [49]. 
This may explain the effect of cholesterol on MHC-II 
antigen presentation [50].
DCs may be unique in that MHC-II transport from 
MIIC is regulated by maturation signals, which 
induce higher MHC-II surface expression at the 
cost of the intracellular pool of MHC-II [51, 52]. 
Lipopolysaccharide triggers the formation of 
tubules that originate from MIIC in DCs, generating 
a complex network of moving vesicles and tubules 
that may all fuse to the plasma membrane [53-55]. 
What controls MHC-II transport in DCs? Two actin-
based motors have been implicated. The common 
actin motor myosin II (MYOII) may interact with Ii 
to control MHC-II transport in DCs [56] (Figure 2E). 
Another pathway controlling MHC-II transport in 
DCs was identified using an integrated siRNA and 
cell biology screen. First, siRNAs affecting MHC-
II expression were defined, then downregulation 
of the target genes upon maturation of DCs was 
determined and the finally remaining candidates 
were silenced in immature DCs. Some of these 
induced redistribution of MHC-II corresponding to 
maturated DCs, while the cells remained immature 
in respect to other activation markers [23]. The 
candidates included GTPase ADP-ribosylation 
factor-like protein 14 (ARL14; also known as ARF7) 
that locates on MIIC, recruits the effector ARF7EP, 
which acts as a receptor for the motor protein 
myosin1E (MYO1E) [23 and Chapter 1 of this thesis]. 
This pathway controls MHC-II export in DCs (Figure 
2E). How maturation signals by LPS control these 
pathways is unclear, yet they may show some 
resemblance to the induced secretion of other 
lysosome-related organelles, such as cytolytic 
granules, melanosomes and Weibel-Palade bodies 
[57].
The End of an MHC-II Molecule
Similar to MHC-I, MHC-II do not have an infinite 
life. However, MHC-II is relatively stable (it has 
already survived late endosomal conditions) and 
does not dissociate at the plasma membrane. In 
addition, the half-life of MHC-II greatly increases 
upon DC maturation [51, 52]. How is it then finally 
degraded? MHC-II (like MHC-I) can be ubiquitylated 
by MARCH1 [58].  Since the expression levels of 
MARCH1– and ubiquitiylation of MHC-II – decrease 
when DCs mature, ubiquitylation was proposed 
to control MHC-II half-life [59]. Interleukin-10 (IL-
10) downregulates surface expression of MHC-II 
and controls the expression of MARCH1 [60, 61]. In 
addition, the co-stimulatory molecule CD83 is highly 
expressed by mature DCs and inhibits the interaction 
between MARCH1 and MHC-II, thereby preventing 
MHC-II ubiquitiylation [62]. These observations 
suggest a causal link between ubiquitylation and 
MHC-II half-life (Figure 2F). However, this link 
has recently been challenged. Mice engineered 
to express MHC-II with mutations that prevent 
its ubiquitylation still show normal antigen 
presentation by MHC-II, although MHC-II expression 
at the plasma membrane was slightly elevated [63]. 
Therefore, MHC-II ubiquitylation may be involved in 
sorting within the endosomal pathway rather than 
endocytosis and degradation [48, 64].
In summary, MHC-II is extraordinary stable but still 
displays cell type-specific half-lives. The control of 
MHC-II degradation has not been established but 
could involve ubiquitylation [63] . Most likely, MHC-II 
ends like any other lysosomal protein by lysosomal 
proteolysis, but the exact mechanism is unresolved. 
The Systems of MHC-II Antigen 
Presentation
Although the system of antigen presentation is 
understood at a high level of detail, this in fact 
only represents sketches of the total biology. For a 
further understanding, modern technologies such 
as siRNA screens allow genome-wide consideration 
of relevant molecular relationships. This can yield 
comprehensive lists of new molecules involved 
in any process. An integration of siRNA data with 
flow cytometry, microscopy and transcriptional 
information from qPCR and microarray yielded 
various novel pathways, placing novel GTPases and 
motor proteins in the control of MHC-II transport 
[23]. Such experimental data sets can be integrated 
with others derived from siRNA screens, genetic 
screens, expression and protein-protein interaction 
data bases to build pathways in silico. These 
pathways then have to be experimentally validated 
to avoid noise in our understanding of the MHC-I and 
MHC-II antigen presentation pathway.
Outside-in Signalling by MHC-II
MHC-II mediate inside-out signalling when presenting 
peptides to T cells, but recent data suggest that 
MHC-II also functions as a signalling receptor, 
resulting in outside-in signalling (reviewed in [65]). 
This can lead to apoptosis of activated APCs and 
results in the termination of immune responses [66]. 
By contrast, engagement of MHC-II on melanoma 
cells by its ligand lymphocyte activation gene 3 
(LAG3) expressed by infiltrating lymphocytes can 
prevent cell death by activating survival pathways 
[67]. Since MHC-II has short cytoplasmic tails without 
detectable signalling motifs, adaptor molecules 
14
must be involved to transduce the outside-in signals 
[65]. Toll-like receptor (TLR) activation induces 
the association of CD40 and Bruton’s tyrosine 
kinase (BTK) with intracellular MHC-II, resulting in 
prolonged BTK activation and TLR signalling-specific 
gene transcription [68]. In addition to CD40, the 
B cell receptor complex components CD79a and 
CD79b [69], the IgE receptor [70] and CD19 [71] have 
been reported to be involved in MHC-II-associated 
signal transduction. Signalling through MHC-II is a 
new concept and consequences of this have to be 
revealed in the future.
Conclusions and Perspectives
The biology of MHC-I and MHC-II has been studied 
extensively due to their fundamental role in 
controlling immune responses and their involvement 
in transplantation, infection, vaccination and 
autoimmunity. Understanding MHC-I and MHC-II 
antigen presentation can be – and in fact already is 
– translated into treatment options [72-74]. Deeper 
understanding of antigen presentation by MHC-I 
and MHC-II should result in additional targets for 
therapeutic manipulation of the immune system. 
Many groups have recently uncovered new steps 
in the antigen processing and presentation system. 
However, many unknowns and controversies 
remain. Whether immunodominance of peptides 
can be predicted and why particular MHC-I or MHC-II 
alleles are associated with autoimmune diseases is 
mostly unclear (except for the known link between 
gluten, HLA-DQ2 and HLA-DQ8 and celiac disease 
[75]) but we hope they will be resolved in the coming 
years.
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MHC class II molecules (MHC-II) present peptides to 
T helper cells to facilitate immune responses and are 
strongly linked to autoimmune diseases. To unravel 
processes controlling MHC-II antigen presentation, 
we performed a genome-wide flow cytometry-
based RNAi screen detecting MHC-II expression 
and peptide loading followed by additional high-
throughput assays. All datasets were integrated to 
answer two fundamental questions: what regulates 
tissue-specific MHC-II transcription and what 
controls MHC-II transport in dendritic cells. MHC-
II transcription was controlled by nine regulators 
acting in feedback networks with higher order 
control by signalling pathways including TGFβ. 
MHC-II transport was controlled by the GTPase 
ARL14/ARF7, which recruits the motor myosin 
1E via an effector protein ARF7EP. This complex 
controls movement of MHC-II vesicles along the 
actin cytoskeleton in human dendritic cells (DCs). 
These genome-wide systems analyses have thus 
identified factors and pathways controlling MHC-
II transcription and transport, defining targets for 
manipulation of MHC-II antigen presentation in 
infection and autoimmunity.
Introduction
Major Histocompatibility Complex class II 
molecules (MHC-II) present peptides to CD4+ T 
cells that initiate and control immune responses. 
The expression of MHC-II is mostly restricted to 
professional antigen presenting cells (APCs), such 
as B cells and dendritic cells (DCs), and controlled 
by a transcriptional complex that includes the 
MHC-II transactivator CIITA [1]. Careful regulation 
of expression is needed to prevent uncontrolled 
immune responses. Various allelic forms of MHC-
II are associated with autoimmune diseases [2]. 
The successful presentation of peptides at the cell 
surface involves a series of subcellular events: In the 
ER, MHC-II associates with the invariant chain (Ii) 
that fills the peptide-binding groove and mediates 
transport to late endosomal compartments called 
MHC-II compartments (MIICs) [3, 4]. There, Ii is 
degraded leaving a fragment called CLIP in the 
peptide-binding groove of MHC-II [5]. In parallel, 
endocytosed antigens are degraded into peptides, 
which compete with CLIP for binding to MHC-II in a 
process catalyzed by the chaperone HLA-DM (DM) 
[6, 7] in the intraluminal vesicles of the MIIC [8]. 
Ultimately, MHC-II-containing vesicles and tubules 
fuse with the plasma membrane [9-11] to present the 
peptide-loaded MHC-II to CD4+ T cells. 
Various factors controlling MHC-II expression have 
been identified, such as cytokines that can inhibit 
(IL-10) [12] or upregulate (interferon-γ) [13] MHC-II 
expression. Certain activation signals, such as TLR 
signalling can also upregulate its expression in B 
cells and DCs [14]. IL-10 signalling may upregulate 
MARCH I, which ubiquitinates and shortens MHC-II 
half-life [15]. Other factors such as pH [16], kinases 
[17] and cholesterol [18] affect MHC-II expression 
and antigen presentation. 
As a first step towards a systems-understanding of 
MHC-II antigen presentation, we performed a multi-
dimensional RNAi screen where we investigated 
cell surface expression of MHC-II, as well as peptide 
loading, transcriptional control and intracellular 
distribution in an integrated manner. Combining 
these phenotypic analyses yielded factors and 
pathways controlling MHC-II transcription and 
transport in DCs and defined targets for manipulation 
of MHC-II antigen presentation in infection and 
autoimmunity.
Results
Genome-wide RNAi Screen identifies 
276 Candidate Genes affecting MHC-II 
Expression and Peptide Loading 
MHC-II is selectively expressed by APCs. To identify 
proteins and networks involved in MHC-II expression 
and peptide loading, we selected the human 
melanoma cell line MelJuSo, which expresses 
peptide-loaded MHC-II and all components required 
for MHC-II antigen presentation [11]. Whereas 
MelJuSo is not an immune cell type, it does express 
many immune-specific genes and proteins controlling 
MHC-II transport similar to DCs. APCs express Toll-
like receptors (TLRs) recognizing double-stranded 
siRNA resulting in activation signals that might 
increase MHC-II expression [19, 20]. MelJuSo lacks 
these TLRs and in addition exhibits transfection 
efficiencies greater than 95%, as well as stable MHC-
II expression and peptide loading capacity (data 
not shown). These features, which are essential for 
reliable RNAi screens, are not shared by any primary 
APC tested. 
To visualize the effects of gene knockdown on MHC-
II expression and peptide loading, we used two 
monoclonal antibodies (Figure 1A). Cy5-conjugated 
CerCLIP, which recognizes human MHC-II loaded 
with the residual Ii-derived CLIP fragment, and Cy3-
conjugated L243, which recognizes peptide-loaded 
MHC-II (called HLA-DR). CLIP-loaded MHC-II reflects 
an inefficiency of the loading of antigenic peptide 
on the mature receptor [21], whereas L243 detects 
correctly loaded MHC-II on the plasma membrane 
[22]. MelJuSo cells were transfected with pools of 
siRNAs (four duplexes per target gene) in 96-well 
format targeting 21,245 human genes in total. Three 
days post-transfection, cells were analyzed by flow 
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cytometry to determine peptide loading as well as 
expression levels of MHC-II. The primary screen 
(performed in triplicate) achieved an excellent 
“screening window” (difference of negative and 
positive control) defined by the Z’ factor [23]. All 
parts yielded Z’>0.5 (Figure 1A; Z’ for the kinase sub-
library). Results were z-score normalized. Genes 
whose silencing resulted in a change of L243 or 
CerCLIP staining by |z|>3 (p<0.0027) were considered 
candidates for follow up. These genes were re-
screened in triplicate, resulting in 789 candidate 
proteins with potential functions in controlling MHC-
II expression and peptide loading (Figure 1B). 
To determine which of the 789 candidates identified 
in the screen were expressed in APCs, we performed 
microarray gene expression analysis on human 
primary monocytes, monocyte-derived (activated 
and immature) DCs and naïve or CD40L-activated 
B cells (Table S1, see Chapter 2 of this thesis). Of 
the candidate genes identified in MelJuSo cells, 
532 genes were expressed in one or more human 
primary APC type. Correcting for off-target effects 
(see Experimental Procedures) resulted in 276 
confirmed candidates (Table S2, see Chapter 2 of 
this thesis). These candidates could be divided into 
four groups based on differential staining with L243 
or CerCLIP, which allowed the distinction between 
effects on MHC-II expression versus effects on 
peptide loading, respectively. Most candidate 
proteins identified in the screen appeared to affect 
MHC-II surface expression; only 45 genes specifically 
affected peptide loading (CLIP up; Figure 1B).
Figure 1 | A genome-wide Flow Cytometry-based RNAi Screen
A | MelJuSo transfected with siRNA were analysed for surface expression of peptide- versus CLIP-loaded MHC-II 
by high-throughput flow cytometry using monoclonal antibodies (L243-Cy3 and CerCLIP-Cy5). The graphs show 
representative z-scores of siRNAs without effect (|z|<3; black line), untreated cells (green), HLA-DM-silencing 
(orange) and candidates after normalization (|z|>3; blue). Inlay in the CerCLIP plot shows the Z’-factor for the 
analysis of the kinase sublibrary, representing the detection window between negative (blue) and positive 
controls (red). 
B | Scheme showing the different confirmation steps in the screening procedure resulting in 276 candidate genes 
influencing MHC-II expression and peptide loading. Indicated is the distribution of four phenotypes detected by 
flow cytometry. See also Table S1 and S2 in Chapter 2 of this thesis.
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Candidate Proteins include known MHC-
II Pathway Components and Proteins 
associated with Autoimmunity 
To annotate the function of the 276 identified 
genes, we used database tools to determine tissue 
distribution, potential function, association with 
autoimmune diseases and established function in 
the MHC-II antigen presentation pathway. First, as 
a validation of our method, we interrogated the 
dataset for proteins already known to be involved 
in MHC-II antigen presentation. Thirteen candidates 
have been reported in literature to control MHC-
II antigen presentation (Figure 2A, green/yellow 
proteins), including the MHC-II transcriptional 
regulator CIITA, the HLA-DRA and DRB chains, DM 
and the IL-10 receptor. Another set of 13 proteins 
might indirectly correlate to the pathway through 
inhibitors or as targets of pathogenic immune 
regulators (Figure 2A, blue proteins). For example, 
FKBP3 (FK506-binding protein 3) may be the target 
of FK506 [24]. The target(s) for general kinase 
inhibitor Staurosporine [17] can be included in the 28 
serine/threonine kinases we identified in our screen. 
Also, the immunodeficiency virus (HIV) protein Tat 
has been postulated to control HIV-Tat Interacting 
Protein (HTATIP) [25] (Figure 2A), which we picked 
up in our screen as a regulator of MHC-II peptide 
loading. Hence, some 10% (26 of 276) of our primary 
screen candidates have already been implicated in 
controlling MHC-II expression and peptide loading. 
In our initial screen however, we did not identify 
all factors that had been reported in literature to 
control MHC-II function. We thus retested these 
separately, which revealed that most of them 
yielded effects below our cut-off of |z|>3 (Figure S1, 
see Chapter 2 of this thesis). 
Second, to determine which candidate genes 
were selectively expressed in immune tissues, we 
interrogated a gene expression database of 79 
human tissues [26], and compared expression levels 
of each candidate between immune and other 
tissues. The expression of CIITA is limited to antigen 
presenting cells, therefore we used its expression as 
a standard for immune-specificity (Figure 2B). Sixty-
nine of the 276 candidates identified by the RNAi 
screen exhibited selective expression in immune 
tissues (Table S1, see Chapter 2 of this thesis). 
Another interesting group in which some of our 
candidates could be placed were associated with 
autoimmunity. Genetic association studies have 
revealed that MHC-II is the strongest autoimmunity-
associated factor [2] possibly triggering the immune 
response by presenting autoantigens. Comparing 
our candidates involved in MHC-II regulation with 
a database containing genes linked to autoimmune 
diseases (http://geneticassociationdb.nih.gov) 
showed that 8% (21 of 276) were associated with 
autoimmune diseases (Figure 2C). This association, 
together with their immune tissue-specific 
expression pattern, makes some of them attractive 
therapeutic targets for manipulating MHC-II 
function.
A standard protocol in genome-wide screening 
is pathway analysis based on literature. We first 
subclustered candidates into four groups based on 
their flow cytometry parameters (Figure 1B) before 
functional annotation by Ingenuity Pathway Analysis 
(www.ingenuity.com, Figure 2D; Table S2, see 
Chapter 2 of this thesis). Many enzyme classes are 
found to be involved in MHC-II antigen presentation, 
but the majority of genes had no ascribed function. 
The four groups were then analyzed by Ingenuity 
Pathways Analysis and STRING [27] for established 
protein interactions and yielded several networks 
consisting of annotated proteins only (Figure S2, see 
Chapter 2 of this thesis). Analysis of these networks 
revealed clusters of proteins already known to 
be involved in MHC-II antigen presentation. No 
novel clusters regulating MHC-II became apparent 
from this network analysis. As most proteins had 
unknown functions, these pathways only covered 
a small fraction of candidate proteins. Hence, 
network analysis using different database tools was 
unsatisfactory in terms of describing the systems 
biology of MHC-II antigen presentation. 
Therefore, we aimed at placing candidates in 
functional networks following secondary high-
throughput screens. We broke down MHC-II antigen 
presentation in three processes: peptide loading (1), 
transcriptional regulation (2), and the general cell 
biology of MHC-II (3). The latter category consists 
of the assembly, intracellular transport, processing 
in the MIIC, endo- and exocytosis. Factors affecting 
peptide loading (1) were already identified by the 
antibody CerCLIP in the primary screen. 
After genome-wide screening we were able 
to confirm our strategy by identifying known 
members of the MHC-II pathway. Furthermore, 
we have highlighted interesting therapy targets 
displaying immune-tissue specific expression and 
association to autoimmune diseases. Secondary 
high-throughput assays are needed to decipher the 
candidates involved in the transcriptional regulation 
and general cell biology of MHC-II. 
Nine Candidates are implicated in 
Transcriptional and Higher Order Control 
of MHC-II Expression
MHC-II mRNA expression is controlled by CIITA. 
To determine whether the 276 candidate genes 
identified in the earlier RNAi screen affected MHC-
II transcription, we silenced the 276 candidates in 
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Figure 2 | Candidate Gene Annotation 
A | A literature-based model representing proteins directly (yellow) and indirectly (blue) involved in the MHC-II 
pathway (green). See also Figure S1 in Chapter 2 of this thesis. EE = Early Endosome; MIIC = MHC class II containing 
Compartment; Ii = invariant chain
B | Gene expression ratios of the candidate genes in the primary human immune cells (1) used in our selection 
procedure (Figure 1B) and immune tissues (2) versus non-immune tissues (3). Grey areas indicate absence of 
probes on the expression arrays. Expression levels of (2) and (3) were obtained from the BioGPS application. 
C | Genes from the screen that are associated to autoimmune diseases based on the Genetic Association Database.
D | Functional annotation of the candidate genes involved in the various effects on MHC-II antigen presentation. 
Annotation retrieved from Ingenuity Pathways Analysis. 
See also Figure S2 and Table S1 and S2 in Chapter 2 of this thesis.
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MelJuSo cells and performed quantitative PCR for 
mRNA of MHC-II (HLA-DRA), CIITA, and Ii. To check 
whether the candidates from our screen controlled 
the entire MHC locus, MHC class I transcription (HLA-
A/B/C) was assessed [28].  
The silencing of nine candidate proteins affected 
transcription of one or several of the tested genes 
(Figure 3A, Table S3, see Chapter 2 of this thesis). 
Silencing of three candidate genes (CIITA itself, 
RMND5B and PLEKHA4) down-regulated CIITA and 
HLA-DR mRNA levels: The protein RMND5B has an 
unknown function and PLEKHA4 has so far only been 
described as a phosphoinositide binding protein. 
The silencing of three other genes (KIAA1007 
[CNOT1], CDCA3 and MAPK1) up-regulated both 
CIITA and HLA-DR transcription. CNOT1 is part of a 
transcription regulatory complex called CCR4-NOT. 
This complex contains also another protein identified 
in our primary screen, called CNOT2. MAPK1, is a 
key signalling intermediate in many well-studied 
pathways and the function of CDCA3 is yet unknown. 
MAPK1 (and CIITA itself) were the only genes shown 
to affect the whole MHC-locus, as measured by MHC 
class I (MHC-I) expression. 
Knockdown of unknown EFHD2 and HTATIP 
increased the expression levels of HLA-DR and 
Ii. Silencing of only one gene (IL27RA, the IL-27 
receptor) affected MHC-I expression independently 
of CIITA. This probably represents a more locus-
specific effect. IL-27RA has been implicated in Th1-
type as well as innate immune responses. For a full 
description of the candidates that affect MHC-II 
transcription see Table S3 in Chapter 2 of this thesis. 
These nine candidate genes, including CNOT2, can 
affect each other’s expression as well as that of 
CIITA, HLA-DR, Ii and MHC-I. To define potential 
interconnections, we performed a ‘cross-correlative 
qPCR’: Each candidate was silenced and the effect on 
expression of the other candidates was determined 
by qPCR (Figure 3B). Most siRNAs affected the 
expression of one or more other candidate genes, 
suggesting that they act in complex networks 
(Figure 3C). These networks can be either defined 
as controlling the CIITA expression (network 1), the 
MHC locus (network 2) or the selective transcription 
of HLA-DR and Ii (group 3). 
We performed literature analysis to define higher 
order regulation of the transcriptional network 
controlling MHC-II expression. Seven of the 
candidates affecting MHC-II transcription have 
already been annotated to pathways. FLJ22318/
RMND5B (human homologue of yeast Required 
for Meiotic Nuclear Division 5B protein), on the 
other hand, is not functionally annotated, but an 
interaction with SMAD4 has been reported [29]. 
SMAD-proteins transduce signals from the TGFβ 
receptor to the nucleus to downregulate MHC-
II expression [30]. To understand the role of this 
unknown factor, we tested whether RMND5B is 
involved in TGFb signaling. Following exposure to 
TGFβ for three days, MHC-II was downregulated in 
MelJuSo. RMND5B silencing further downregulated 
MHC-II expression as detected by flow cytometry 
and qPCR (Figure 3D, E). RMND5B might thus act 
as an inhibitor of SMADs. SMAD4 translocates from 
cytosol to nucleus upon TGFβ exposure [31], which 
was also observed for RMND5B in MelJuSo (Figure 
3F). Although we failed to show a direct interaction 
with SMAD4, we placed RMND5B in a network 
controlled by TGFβ signaling, which controls MHC-II 
expression. 
We have defined a transcriptional network 
controlling MHC-II expression. Furthermore, we 
described a network of higher order control based 
on proteins annotated in literature (Figure 3G; for 
references Figure S3 in Chapter 2 of this thesis). 
These networks should in principle explain the 
immune tissue-selective expression of MHC-II. The 
data show that CIITA expression is controlled by a 
complex transcriptional feedback mechanism, which 
in turn is controlled by a series of general biological 
processes such as chromatin modification, the cell 
cycle and a number of different signaling events 
including those mediated by TGFb and RMND5B. The 
combined input of events presumably determines 
the tissue selectivity of MHC-II expression.  
Analysis of Networks with similar 
intracellular MHC-II Distribution 
Phenotypes selects Candidates for in-
depth Study 
Nine candidate genes were shown to control 
the transcription of MHC-II. This implies that the 
other 268 candidates could affect the intracellular 
distribution of MHC-II. This we evaluated by 
microscopy. A clonal MelJuSo cell line expressing 
MHC-II-GFP and mCherry-GalT2 (a Golgi marker) was 
transfected with siRNAs for the candidates. The 
nuclei (Hoechst) and early endosomes (anti-EEA1) 
were stained to detect all relevant intracellular 
compartments of MHC-II (Figure 4A and S4A, see 
Chapter 2 of this thesis). The resulting images were 
processed with CellProfiler software [32], which 
resulted in more than 100 parameters describing 
the features of nuclei, endosomes, Golgi and plasma 
membrane. Images were analyzed and scored using 
automated image analysis software (CPAnalyst2; 
see Supplemental Experimental Procedures for 
analysis parameters in Chapter 2 of this thesis) [33]. 
Particular phenotypes could be characterised in 
this manner: e.g. enlarged MHC-II positive vesicles, 
MHC-II redistribution to the plasma membrane, 
clustering or dispersion of early endosomes, and 
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Figure 3 | MHC-II Transcription Control Networks and higher Order Control 
A | The heatmap shows the log-transformed expression values (GAPDH as reference) relative to siControl-treated 
cells (FLJ22318 = RMND5B; KIAA1007 = CNOT1). Mean values of four independent experiments are shown. Stars 
show correlation between L243 phenotype (Table S2, in Chapter 2 of this thesis) and qPCR.
B | Upon silencing the genes defined under (A), the effect on the expression levels of the nine genes and the MHC-
II factors were determined by qPCR. Confirmed effects of at least two experiments are shown (green = down-; 
red = up-regulation; gray = no effect).
C | Transcriptional networks deduced from the qPCR data controlling CIITA (1), the MHC locus (2) or MHC-II and 
Ii expression without CIITA involvement (3). Intracellular localisation of the proteins is represented in different 
colours. Red arrows: inhibition, green arrows: activation of transcription.
D | MHC-II expression on RMND5B silenced MelJuSo cells in presence or absence of TGFb. Mean fluorescence 
intensity of three experiments plus standard deviation normalized to control siRNA conditions is plotted. 
* p<0.05
E | RNA levels of HLA-DR upon RMND5B silencing and TGFb treatment. LOG-transformed expression levels 
(relative to GAPDH) from two experiments normalized to control siRNA conditions plus standard deviation are 
plotted. *p<0.05
F | Intracellular distribution of RMND5B and SMAD4 in MelJuSo in the presence or absence of TGFb. (bar = 10 mm)
G | Higher order control of the transcriptional network, based on literature and experimental data (red box). 
See also Figure S3 and Table S3 in Chapter 2 of this thesis.   
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Figure 4| MHC-II Distribution Control: Automated  Image Analysis 
A | MelJuSo stably expressing MHC-II (HLA-DRB1-GFP, green) and a Golgi marker (mCherry-GalT2, red) were 
transfected with siRNA targeting the 276 candidate genes and stained for early endosomes (EEA1) in blue and 
nucleus (Hoechst, not shown). 
B | Confocal images of all silenced genes were analysed using CellProfiler and CPAnalyst 2. In the process of 
‘supervised machine learning’, siRNAs resulting in similar phenotypes were manually grouped into several 
bins for the different fluorescent channels. Shown are panels with representative images used for computer 
instruction. The minimal number of descriptive parameters for each group was determined.
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altered Golgi structure (Figure 4B). After several 
rounds of software training, the minimal number of 
parameters (out of the >100) needed to distinguish 
the phenotypes was determined (Figure S4B and 
Table S4, see Chapter 2 of this thesis). After z-score 
normalization, the siRNAs giving similar phenotypes 
were clustered (Figure 4C). Control siRNAs (positive 
and non-affecting) were clustered in distinct groups, 
thereby validating our method. 
To obtain an overview of our data, we built a network 
tree integrating information of all the different 
screens. The fill-color of each gene shows the effect 
on MHC-II surface expression (L243, flow cytometry 
screen), while the color of the edge represents 
mRNA level changes going from immature (im)DCs 
to mature (m)DCs, as found by microarray. The size 
of the node correlates to an increase in the relative 
amount of MHC-II at the surface, an mDC-like 
phenotype [34, 35]. This feature was deduced from 
the microscopic analysis (Table S4, see Chapter 2 of 
this thesis). Candidate genes grouped in the same 
branch of the diagram, due to similar phenotypes 
generated, were postulated to act in the same 
functional pathways. We set an arbitrary threshold 
to distinguish four highly homologous clusters in 
our tree diagram (distance to root ≥153.6, genes 
per cluster ≥15, indicated by blue lines in Figure 
4C, see also Figure S5 in Chapter 2 of this thesis). 
These clusters included also unknown proteins that 
might be functionally connected to known proteins 
present in the same cluster. These connections may 
be better understood after in-depth experimental 
validation.   
To understand the function of the identified 
clusters, we determined the enrichment of Gene 
Ontology (GO) terms. As expected, all candidates 
identified by the screens were enriched for the GO 
cellular component term ‘MHC-II protein complex’ 
(p=0.0028815, Table S5, see Chapter 2 of this 
thesis). For a more extensive analyses, we applied 
the integrated functional gene network program 
Humannet v. 1 [36] that combines information from 
several expression and protein-protein interaction 
databases. We first measured the degree of 
connectivity between our candidates by the Area 
Under the Receiver Operating Characteristic (ROC) 
Curve (AUC) (Figure S6, see Chapter 2 of this thesis). 
The AUC of 0.6175 indicates that many connected 
genes (neighbours) also genuinely interact. 
Neighbours with a log-likelihood score ≥1 according 
to Humannet and a |z| ≥1.645 (p<0.1) in our original 
flow cytometry screen were also included in this 
analysis (Table S6, see Chapter 2 of this thesis). 
These increased the number of proteins involved 
in the same functional pathway. Subsequent GO 
analysis of the expanded groups indicated that 
clusters 2 and 4 (Figure 4C) were enriched for ‘MHC-
II protein complex’ (Table S5, see Chapter 2 of this 
thesis). When we combined this information with 
the microscopy phenotypes we noted that the genes 
in cluster 4 did not affect MHC-II distribution while 
those in cluster 2 showed MHC-II redistribution to 
the cell surface which resembles an mDC phenotype 
(Figure 6A). Cluster 2 has two areas where the 
genes cohered (Figure 5A), one was enriched for GO 
terms like ‘MHC-II protein complex’ (Figure 5B) and 
another for ‘cytosolic ribosome’ terms [cells with 
reduced intracellular MHC-II; (data not shown)]. 
The definition of clusters combined with functional 
annotation predicts connections between 
candidates within a network. This allows the 
addition of genes to these networks, which were not 
originally identified in our siRNA screen (for reasons 
of functional redundancy, effect below cut-off etc.). 
Our integrative bioinformatic approach enables us 
to select candidates for further biochemical studies 
based on their predicted functional relationships 
and effects observed in our various screens.
Six Proteins involved in MHC-II 
Redistribution in maturing DCs
To test whether our networks indeed predict 
processes essential in the immune system, we 
studied MHC-II distribution in DCs. DCs exposed to 
maturation signals redistribute MHC-II molecules 
and various activation markers from CD63-positive 
vesicles to the plasma membrane, enhancing 
their surface expression. This is an essential step 
in the acceleration of immune responses [34, 35] 
(Figure 6A). MHC-II distribution is visualized in a co-
localisation pixel plot of CD63 versus MHC-II (Figure 
6A, right panel). To select candidates potentially 
involved in the control of MHC-II redistribution in 
DCs, we used the following arguments. Firstly, the 
Figure 4 | continued
C | Organic view of clustered genes based on phenotype determined by quantitative microscopy analysis. The 
color of the nodes indicates the z-score for the L243 staining (red: up-, green: down-regulation). The nodes’ 
border color indicates the change in mRNA levels upon DC maturation (red: higher, green: lower expression). 
Node size represents a measure of mDC phenotype. A larger node is correlated to higher cell membrane MHC-II 
levels related to intracellular vesicles. Names in large font indicate selected candidates for further testing in DCs. 
Example images of genes from selected clusters are shown. (bar = 25 mm) 
See also Figure S4 and S5, Table S4 in Chapter 2 of this thesis.
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genes should up-regulate MHC-II expression at the 
cell surface (as in mDCs). Secondly, if upregulation 
is caused by silencing, the candidate should be 
downregulated in the microarray analyses from 
imDC to mDC. Lastly, silencing of genes should 
induce MHC-II transport to the plasma membrane 
as determined by microscopy (Figure 4C, Table S1, 
S2, see Chapter 2 of this thesis). Nine unrelated 
candidates fulfilled all criteria and we tested 
whether silencing these genes in imDCs could mimic 
the reduction in expression following activation and 
therefore alter the distribution of MHC-II (Figure 6B). 
Four individual shRNA sequences per gene were 
introduced into primary human monocytes, before 
differentiation into imDCs, detected by decreased 
monocyte marker CD14 and increased DC marker 
DC-SIGN expression. Typical activation markers for 
mDCs remained absent (Figure 6C). Seven out of 
nine selected candidates increased CerCLIP and/or 
MHC-II expression in imDCs six days after shRNA 
Figure 5 | MHC-II Distribution Control: Systems Analysis of Biological Pathways
A | Interaction network of genes from cluster 2 (Figure 4C). green: high scoring neighbours with |z|≥1.645 (p=0.1) 
in the original flow cytometry screen, blue: genes from cluster 2. Zoom in on Box 1 is shown. 
B | Gene Ontology analysis of cellular components from the aggregated genes in Box 1. The colours represent 
enrichment for specific GO term (yellow to red: enriched). 
See also Figure S6 and Table S5 and S6 in Chapter 2 of this thesis.
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Figure 6 | MHC-II Redistribution in imDCs
A, F | Immature (imDCs) and maturated (mDCs)  DCs  (A) or manipulated imDCs (F) were stained for MHC-II 
(green), CD63 (blue), actin (phalloidin; red) and nucleus (Hoechst; white) and analyzed by confocal microscopy. 
Shown is the merge and the colocalisation plot per pixel for CD63 versus MHC-II (right panel) with the normalized 
correlation coefficient indicated (bar = 10 µm). 
B | Selected candidate genes with primary screen phenotype (Table S2 in Chapter 2 of this thesis) are indicated. 
C | Cell surface expression levels of monocyte (CD14), DC (DC-SIGN) and maturation markers (CD83, CD40, CD80, 
CD86) are plotted as averages of three donors plus standard deviation relative to levels on imDC. Four individual 
shRNA control vectors (shControl) or shRNAs targeting various candidate genes (shRNA) have been averaged.
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transduction of monocytes (Figure 6D and S7A, see 
Chapter 2 of this thesis), similar to the effects in 
the primary screen. As controls, we silenced CIITA 
and DM, obtaining the anticipated effects on L243 
and CerCLIP levels, respectively. Gene silencing 
was confirmed by qPCR for representative shRNA 
constructs (Figure 6E).
Next, the effect of silencing the nine candidates on 
the distribution of MHC-II in imDCs was studied by 
confocal microscopy. A gallery of representative 
images is shown in Figure S7B in Chapter 2 of 
this thesis. Six candidates showed a significant 
redistribution of MHC-II from CD63-positive 
compartments to the plasma membrane, which 
mimics the distribution of MHC-II in mDCs (Figure 
6F and S7C, see Chapter 2 of this thesis). Silencing 
of undefined proteins FLJ20249 (GPATCH4) and 
FLJ22595 (the small GTPase ARL14/ARF7) as well 
as the transcription factor MAFA strongly affected 
localisation. Redistribution of MHC-II was also 
observed for coat protein complex II protein SEC13L1 
(SEC13), Golgi protein GOLPH3-like GPP34R and 
PDCD1LG1 (CD274), a molecule widely expressed 
on immune cells involved in the regulation of T cell 
responses.  
Our strategy identified proteins controlling MHC-II 
transport in imDC that would not have been selected 
without an unbiased approach. Silencing these 
genes generated imDCs with an mDC-like MHC-
II distribution. These proteins control one of the 
strongest specific responses in the immune system 
and therefore open up points to target manipulation 
strategies at. 
A Pathway of the GTPase ARL14/ARF7 and 
actin-based Motor Myosin 1E controls 
MHC-II Transport in DC
 We defined various proteins controlling MHC-II 
transport in DCs. One of these, the GTPase ARL14/
ARF7 was detected on MHC-II vesicles in imDCs 
(Figure 7A) and selected as a starting point for 
building a pathway aimed at understanding the 
molecular basis of MHC-II transport in DCs. Guanine 
Exchange Factors (GEFs) activating ARF GTPases 
are specified by SEC7 domains [37]. We scanned the 
dataset of the primary screen (Figure 1) for proteins 
containing SEC7 domains that upregulated MHC-II 
expression, similar to ARL14/ARF7. Two candidate 
GEFs were identified. Their SEC7 domains were 
expressed as MBP-tagged proteins for in vitro 
GTP loading assays of GST-ARL14/ARF7 and GST-
ARF6 as control. Only PSD4/EFA6B/TIC (selectively 
expressed in the immune system, z=2.22 in RNAi 
screen) promoted GTP loading of ARF6, as described 
[38] and ARL14/ARF7 (Figure 7B). The PH-domain of 
PSD4 was produced as GST-fusion protein and used 
in a lipid-binding assay which indicated specificity 
for various PIP2 species (Figure 7C). The candidates 
for controlling MHC-II transport in DC (Figure 6B) 
also included a regulatory subunit of PI3K (PIK3R2) 
[39] and PIP5K1A, which can generate PIP2. 
Overexpressed GFP-PIP5K1A localized to the plasma 
membrane and partly colocalized with intracellular 
MHC-II and ARL14/ARF7-mCherry vesicles in MelJuSo 
cells (Figure 7D) and phagosomes [40]. Collectively, 
this reveals part of a pathway where PIP5K1A and 
PIK3R2 create PIPs required for recruitment or 
activation of the GEF PSD4 which activates ARL14/
ARF7.
GTPases require effectors to transmit function. We 
performed Yeast Two-Hybrid with ARL14/ARF7 as 
bait to identify C11ORF46 (now called ARF7 Effector 
Protein or ARF7EP) (Table S7, see Chapter 2 of 
this thesis). This 29 kDa protein does not have any 
detectable domains and is selectively expressed in 
the immune system. The interaction was confirmed 
by isolating ARL14/ARF7 with ARF7EP from lysates 
of MelJuSo expressing HA-ARF7EP and RFP-ARL14/
ARF7 (Figure 7E). Immunostaining of MelJuSo cells 
expressing both proteins confirmed co-localization 
of ARL14/ARF7 and ARF7EP (Figure 7F). 
Since ARF7EP does not provide any structural 
information that connects it to a biological pathway, 
we performed pull-down experiments with GST 
or GST-ARF7EP in cytosolic extracts of human 
PBMCs. Proteins found in the GST-ARF7EP isolate 
Figure 6 | continued
D | Median z-score of three donors in flow cytometry after silencing candidates in imDCs plotted for one 
representative shRNA construct per gene. The grey box highlights the cut-off. Stars indicate confirmation 
of phenotype as observed in MelJuSo cells (black confirmation by >1 shRNA constructs, grey by one shRNA 
construct). 
E | Knockdown levels determined by qPCR represented as normalized RNA levels relative to control shRNA treated 
cells of one donor. Two representative constructs are shown per gene. Averages plus standard deviations are 
plotted. n.a. not analyzed
F | Representative microscopy images of three confirmed candidates silenced by lentiviral shRNA in imDC with 
intracellular effects on MHC-II redistribution. The colocalisation coefficient was normalized to control shRNA-
treated cells and determined by Cell Profiler. (bar = 10mm). 
See also Figure S7 in Chapter 2 of this thesis.
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Figure 7 | Data-based Systems Determination of PIP5K-ARL14-MYO1E Pathway of MHC-II transport Control in 
imDC
A | Immature human monocyte-derived DCs were fixed and stained for nucleus (blue), MHC-II (green) and ARL14/
ARF7 (2C8, red). (bar = 10 mm)
B | In vitro a32P-GTP loading of ARL14/ARF7 and ARF6 by SEC7 domains of predicted GEFs CYTH1 and PSD4. 
Results are normalized to spontaneous loading of the two GTPases. Shown are average and standard deviation 
of triplicate experiments.
C | Phospholipids spotted on a membrane were probed with the GST-purified PH domain of PSD4. 
D | MelJuSo cells were transfected with ARL14/ARF7-RFP and GFP-PIP5K1A, fixed and stained for MHC-II. Arrows 
indicate colocalisation on vesicles. (bar = 10 mm)
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were identified by mass spectrometry as B-actin 
and actin-based motor protein myosin 1E (MYO1E). 
Pull–down experiments from HEK293T extracts 
showed specific recovery of GFP-tagged MYO1E 
by GST-tagged ARF7EP (Figure 7G). MYO1E is a 
single-headed actin-based motor highly expressed 
in the immune system. ARL14/ARF7 may connect 
to the actin network via ARF7EP-MYO1E to control 
export of MHC-II. To test this connection, human 
imDC were stained with anti-actin and anti-ARL14/
ARF7 antibodies (Figure 7H) revealing ARL14/ARF7 
containing vesicles aligning with actin cables. The 
interaction between ARF7EP and MYO1E was further 
confirmed by immune precipitation from extracts of 
human PBMC (Figure 7I). 
Various assays were integrated with the results of 
the RNAi screen to place proteins in one immune 
specific pathway of actin-based control of MHC-II 
transport in imDC (Figure 7J). Manipulation of this 
pathway in imDCs to induce the characteristic MHC-
II transport from intracellular stores to the plasma 
membrane could be the result of inactivation of the 
ARF7GEF PSD4 by changed behavior of PI3 and PI5 
kinases. How these events are controlled in DCs 
during activation is unknown. By extensive dataset 
integration, we defined a pathway controlling one of 
the most essential steps in immune cell activation; 
the redistribution of MHC-II to the plasma membrane 
in DCs after maturation.         
 
Discussion
We describe here the genome-wide analysis of an 
essential process in the immune system: antigen 
presentation by MHC-II. We identify 276 candidates 
with only 10% described thus far in the MHC-II 
pathway. Twenty-one candidates are linked to 
autoimmune diseases. As in our siRNA experiments, 
these genes may cause aberrant MHC-II expression 
Figure 7 | continued
E | Immunoprecipitation (IP) of ARL14/ARF7-RFP and HA-ARF7EP expressed in MelJuSo with anti-RFP. 
Immunoblots were probed with HA and ARL14.2 antibodies. Molecular weight standard is indicated. See also 
Table S7 in Chapter 2 of this thesis.
F | Immunofluorescence of MelJuSo expressing ARL14/ARF7-RFP and GFP-ARF7EP methanol-fixed and stained 
with ARF7EP antibody. (bar = 10 mm)
G | Pull-down of GFP-MYO1E expressed in HEK293T with recombinant GST-ARF7EP or GST (control) coupled 
to Glutathione beads. Immunoblots were probed with GST and GFP antibodies. Molecular weight standard is 
indicated. 
H | imDC stained for endogenous actin and ARL14/ARF7 (ARL14.2). Two zoom-ins are shown. (bar = 10 mm).
I | IP of endogenous ARF7EP and MYO1E in human PBMC with anti-ARF7EP or anti-GFP (Control). Immunoblots 
were probed with MYO1E and ARF7EP antibodies. Molecular weight standard is indicated. 
J | Summarized pathway of actin-based control of MHC-II in imDC. Red proteins; candidates from the screen with 
|z|>3; Blue proteins with |z|<3. Identification and confirmation of the various proteins is indicated. PI kinases 
create substrates for the GEF PSD4 required for ARL14/ARF7 activation. The effector ARF7EP and MYO1E connect 
to actin.
in patients, which requires further experimental 
validation before consideration for therapeutic 
manipulation.  
We have developed various methods to place the 
candidate genes in the systems of transcriptional 
and cell biological control of MHC-II antigen 
presentation. By flow cytometry we selected 45 
genes affecting peptide loading only, including 
HLA-DM and components of the ESCRT machinery 
involved in multivesicular body formation. A 
limited set of genes could be placed in networks 
by computer-based pathway analysis, unlike the 
majority of genes, which have an unknown function. 
This represents an enigma in high-throughput 
screening yielding large datasets and often results 
in preselecting one gene for in-depth analysis with 
limited new understanding of biology. 
There are two important unelucidated processes in 
MHC-II antigen presentation, which we addressed 
in our study in detail: the control of tissue specific 
expression of MHC-II and the regulation of MHC-II 
distribution in DCs. MHC-II expression is controlled 
by CIITA. How CIITA in turn is regulated is unclear. 
We discovered nine transcriptional regulators of 
MHC-II expression and performed cross-correlative 
qPCR to determine their interrelationships and 
their effects on CIITA expression. Five of these 
regulate the expression levels of CIITA in a complex 
feedback loop involving the (yeast meiosis) factor 
RMND5B and MAPK1 that phosphorylates and 
influences CIITA activity [41]. The remaining factors 
control MHC-II expression without affecting CIITA 
levels. This includes the HIV Tat interacting protein 
HTATIP, a histone modifier that may mediate Tat 
control of MHC-II expression [25, 42]. By combining 
experimental and literature data, we show that 
the activities of extracellular signalling, the cell 
cycle and chromatin modifications control the 
transcriptional network for immune tissue-restricted 
MHC-II expression. Of note, pathogens also 
34
manipulate these pathways; HIV targets HTATIP and 
L. monocytogenes targets SMAD4 [25, 43]. Tissue 
selective expression of MHC-II is thus orchestrated 
by a series of unrelated input signals. The details 
of how these cooperate to induce proper MHC-II 
expression remain unclear. 
To identify proteins controlling MHC-II distribution, 
we silenced all candidates and the effect on MHC-II 
distribution was visualized by microscopy. Candidate 
genes inducing a similar phenotype are expected 
to participate in one network, as illustrated in 
yeast screens that identified the ESCRT machinery 
[44]. We integrated our phenotypic clusters 
with databases like Humannet v. 1 to expand our 
networks and annotated these using GO analyses. 
Half of the genes in these clusters were predicted 
to control MHC-II trafficking but will require further 
experiments to validate their place in networks. 
To select candidates involved in MHC-II redistribution 
in DCs, expression and functional RNAi datasets 
were combined to define six proteins controlling 
MHC-II transport. Silencing these resulted in imDCs 
with an mDC-like MHC-II distribution. These six 
candidates could act in one or parallel pathways.  
One candidate, ARL14/ARF7, is a GTPase selectively 
expressed in immune cells. To build a pathway, we 
first localized ARL14/ARF7 on MHC-II compartments 
in imDC. Using domain predictions and in vitro 
assays, we defined the GEF for ARL14/ARF7 as PSD4. 
PSD4 contains a PH-domain with specificity for 
various PIP2 species which may result from activities 
of two other proteins proposed to control MHC-
II distribution in DCs: PIK3R2 and PIP5K1A. While 
PI(3,5)P2 locates to late endosomes [45], the PH-
domain of PSD4 has a broader specificity and can 
therefore not induce selective targeting of PSD4 to 
late endosomes. The 60 kDa N-terminal domain of 
PSD4 may induce targeting to endosomal vesicles 
[38]. When detecting PIP2, the PH domain of PSD4 
might position the preceding SEC7 domain correctly 
for supporting GTP loading of ARL14/ARF7. To 
further expand the network, an interaction of the 
ARL14/ARF7 effector ARF7EP with the actin-based 
motor MYO1E was defined. This pathway connects 
general signalling events to actin-based transport 
control of MHC-II compartments in DCs.
While PIK3R2 and PIP5K1A upstream are broadly 
expressed proteins, the other proteins in this 
pathway are more immune system selective. Of note, 
another candidate for controlling MHC-II distribution 
in DCs, PDCD1LG1 (CD274, PD-L1) activates PI3K via 
its receptor PD-1. PD-1 delivers inhibitory signals 
regulating T cell activation and tolerance. Little is 
known about PD-L1 signalling [46] and this signalling 
may be irrelevant in mDC [47]. Tissue selective 
control of actin-based transport by GTPases has 
been shown before for melanosomes where GTPase 
RAB27a binds MYO5A via its effector Melanophylin 
[48]. MYO1E may be involved in granule secretion 
[49] as well as endocytosis by coupling to dynamin 
[50]. MYO1E may have multiple functions in actin-
based processes depending on recruitment to 
specific locations. We define ARL14/ARF7-ARF7EP 
as a MYO1E receptor on MHC-II compartments for 
actin-based transport control. How the previously 
observed interaction between another actin-based 
motor MYH9 and MHC-II-associated Ii contributes to 
this process is unclear [51]. 
The four remaining proteins controlling MHC-
II transport in imDC could not be placed in this 
pathway: MAFA is a transcription factor for insulin 
in pancreatic beta cells [52]. Our microarray data do 
not show any insulin production in DCs because the 
transcription co-factors Pdx-1 and NeuroD1 [53] are 
not expressed. SEC13L1 (SEC13) is a COPII protein 
controlling transport between ER and Golgi [54] 
which is a non immune-specific process in cells. 
GOLPH3L might have a similar function in the Golgi 
as GOLPH3 [55]. The function of the fourth protein, 
GPATCH4 is unknown. It remains to be elucidated 
whether and how GPATCH4 could manipulate MHC-
II antigen presentation.  
We describe here a genome-wide analysis of 
molecules acting on a central controller in the immune 
system: MHC-II. After a first candidate selection by 
flow cytometry, we applied two additional high-
throughput techniques and integrated the data with 
expression and protein interaction databases, cross-
correlative qPCR, Yeast Two-Hybrid and proteomics. 
We defined a transcriptional network for MHC-II and 
CIITA, and a cell biological pathway placing ARL14/
ARF7, its effector ARF7EP and MYO1E in control 
of actin-based MHC-II transport in DCs. This study 
identifies new targets and pathways for chemical 
and biological manipulation of MHC-II expression in 
various diseases, including autoimmunity.
Experimental Procedures
siRNA Transfection, Flow cytometry and 
Microarray
Gene silencing was performed in the human 
melanoma cell line (MelJuSo) using DharmaFECT 
transfection reagent #1 and 50 nM siRNA (Human 
siGenome SMARTpool library, Dharmacon). Three 
days post-transfection, cells were analyzed by flow 
cytometry (BD FACSArray) using L243-Cy3 [22] 
and CerCLIP-Cy5 [21] monoclonal antibodies. The 
data was normalized (cellHTS, Bioconductor) and 
transformed into z-scores [56]. Expression levels 
of genes with |z|>3 were determined by microarray 
analysis (Illumina) in primary human monocytes, DCs 
and B cells; isolated and differentiated as previously 
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described [57, 58]. Mature DCs were generated by 
culturing for two days in the presence of 2.5 µg/
ml LPS (Invivogen) and 1000 U/ml IFNγ (Immukine, 
Boehringer Ingelheim). 
For statistical analysis, p-values were determined 
using the Student’s t test.
Quantitative RT-PCR
Messenger RNA was extracted (mRNA Capture Kit) 
and reverse transcribed into cDNA (Transcriptor 
High Fidelity cDNA Synthesis Kit). The quantitative 
RT-PCR was performed using LightCycler® 480 SYBR 
Green 1 Master on the LightCycler® 480 Detection 
System (all Roche). Quantification was performed 
using the comparative CT method (DDCT). Primer 
sequences are available upon request.
Confocal Microscopy
Distribution of MHC-II, early endosomes and Golgi 
was visualized by confocal microscopy (Leica AOBS 
microscope) using MelJuSo stably expressing HLA-
DRB1-GFP, mCherry-GalT2 and stained with anti-
EEA1 (BD transduction laboratories) and Hoechst 
(Invitrogen). DCs were stained using Hoechst, 
Phalloidin-Alexa568 (Molecular Probes), anti-ARL14 
2C8 (BioConnect), anti-CD63 (NKI-C3) and anti-HLA-
DR [3]. Images were analyzed using CellProfiler 
1.0.5811 [32]. CPAnalyst 2 was used to determine 
the minimal set of parameters needed to describe 
the relevant phenotypes [33]. The “Measure 
Correlation” module of CellProfiler was used to 
determine the correlation between CD63 and MHC-
II. MelJuSo cells were cultured with 3 ng/ml TGFβ 
for three days. Cells were stained with anti-SMAD4 
(Santa Cruz) and anti-RMND5B (Abcam) antibodies. 
Open and proprietary software was used for 
pathway analysis as described extensively in the 
Supplemental Experimental Procedures.
DC Manipulation
Human primary monocytes were transduced 
with lentiviral particles in the presence of 4 µg/ml 
polybrene (Millipore) at a MOI of 2. Viruses were 
produced by 293T cells transfected with packaging 
(pRSVrev, pHCMV-G VSV-G, pMDLg/pRRE) and 
pLKO.1shRNA constructs (Open Biosystems, Thermo 
Scientific) using Fugene 6 (Roche). Monocytes were 
subsequently cultured for six days in the presence of 
800 U/ml IL-4 and 1,000 U/ml GM-CSF (Cellgenix) to 
generate imDCs. DC cell surface marker levels were 
determined by flow cytometry after staining with 
the following mouse anti-human antibodies: FITC 
CD14, APC DC-SIGN, PE HLA-DR (L243), FITC CD83, 
APC CD40, PE CD80, APC CD86 (all from BD).
Pathway building Techniques 
Yeast Two-Hybrid was performed at DKFZ 
(Heidelberg) with ARL14-Q68L without 
myristoylation site cloned in pGBT9.  ARF7EP 
was cloned in a bacterial expression vector as 
a GST-chimera and purified. Recombinant GST-
ARF7EP and GST as a control were used to fish for 
endogenous MYO1E from cytosolic extracts of 
human PBMCs and bound fractions were analyzed 
by mass spectrometry. Biochemical GEF assays were 
performed with purified MBP-tagged SEC7 domains 
from CYTH1 and PSD4 and GST-purified ARL14 or 
ARF6 using a32P-GTP. The PH domain of PSD4 was 
isolated as a GST-PHPH protein from 293T cells and 
used to probe phospholipid membranes (tebu-bio). 
For antibodies used to immune precipitate see 
Supplemental Experimental Procedures in Chapter 
2 of this thesis.
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Supplemental Experimental Procedures
Cell Lines
Wild-type (wt) MelJuSo, human melanoma cell line, 
expressing HLA-DRB3 [17], was cultured in IMDM 
(Gibco) supplemented with 7.5% fetal calf serum (FCS, 
Greiner). MelJuSo were transfected with HLA-DRB1-
GFP and mCherry-GalT2, stable clones were selected 
and cultured in IMDM/7.5% FCS supplemented with 
Penicillin/Streptomycin (Invitrogen), Hygromycin 
(Invitrogen) and Neomycin/G418 (Gibco). Human 
293T cells were cultured in DMEM (Gibco) 
supplemented with 7.5% fetal calf serum (FCS, 
Greiner) and Penicillin/Streptomycin (Invitrogen).
Constructs
HLA-DRB1-GFP from pCDNA3-DR1B-GFP [18] was 
cloned into pCDNA3 via HindIII-XhoI. GalT2 was 
removed via EcoR1-BamH1 from GalNac-T2-GFP [19] 
construct (generous gift from T. Nilson) and placed 
into pmCherry-C1, where we replaced GFP from 
pEGFP-C1 [20] (Clontech) for mCherry via NheI and 
BglI.
The packaging constructs used for lentivirus 
production are as follows, pMDLg/pRRE, pRSV-Rev 
and pCMV-VSV-G [21], kindly provided by Dr. M. 
Soengas (University of Michigan, USA). The pLKO.1 
plasmids containing shRNA hairpins targeting 
selected genes were purified from bacterial glycerol 
stocks (Open Biosystems, Thermo Scientific) using 
a large scale plasmid DNA purification kit (Qiagen). 
The vectors pLKO.1 empty, pLKO.1 EGFP shRNA, 
pLKO.1 TurboGFP shRNA, pLKO.1 Luciferase shRNA 
and pLKO.1 non-target shRNA served as negative 
controls.
ARL14/ARF7 Q68L missing the sequence coding for 
the myristoylation site (first two N-terminal amino 
acids) was amplified from IMAGE: 4747382 and 
cloned into pGBT9 via EcoRI and BamH1 restriction 
sites to use for Yeast Two-Hybrid assay. ARL14/ARF7 
was cloned, using restriction sites EcoRI and BamHI, 
into pRP265 and mCherry-N1 via EcoRI and BamHI. 
ARF7EP was amplified form IMAGE clone 6062049 
and cloned into pRP265 and p2HA-C1 via BglII 
and EcoRI (p2HA-C1 was retrieved from pEGFP-C1 
(Clontech) where GFP was exchanged for HA-HA 
using Nhe1 and BglII cloning sites). Those constructs 
were used for protein production, co-immune 
precipitation and colocalization experiments. SEC7 
domains of PSD4 (aa555-aa738) and CYTH1 (aa73-
aa202) were amplified from IMAGE clone 5757431 
(PSD4) and IMAGE clone 4755203 (CYTH1) and 
cloned into pMAL-c2X using BamHI and HinDIII 
restriction sites. Double PH-domains of PSD4 (aa776-
aa892) were amplified and cloned into pRP265 and 
pEGFP-N1 using BglII, EcoRI and BamH1 for lipid 
binding. pGEX-Arf6 was a generous gift from Dr. C. 
D'Souza-Schorey (University of Notre Dame, FR). 
GFP-PIP5K1A GFP was a generous gift from Dr. N. 
Divecha (The University of Manchester,UK) [22]. 
Myo1E and Myo1E tail (aa710-aa1109) both amplified 
from IMAGE clone 30527536 were cloned into 
pEGFP-C1 using Asp718I and BamHI as restriction 
sites.
Antibodies
The hybridoma cell lines L243 (anti-HLA-DR complex, 
ATCC) and CerCLIP.1 (anti-CLIP24) have been 
described previously [23, 24]. Cells were maintained 
in IMDM/7.5% FCS, penicillin/streptomycin and 
gentamycin (Gibco). The monoclonal antibodies 
were purified, concentrated by HPLC and 
affinity purified using protein G-sepharose beads 
(Amersham Biosciences). L243 and CerCLIP 
antibodies were directly conjugated to Cy3 and 
Cy5 fluorophores, respectively and purified by size 
exclusion chromatography. 
Mouse anti-human EEA1 (MAB 610457, BD 
transduction laboratories), Hoechst (2 μg/ml, 
33342, Invitrogen), Phalloidin-Alexa568 (0.4 U/ml, 
Molecular Probes), mouse anti-human CD63 NKI-C3 
[25], mouse anti-human Arl14 (BioConnect), mouse 
anti B-actin (AC-15, Sigma Aldrich) and rabbit anti-
human HLA-DR [26, 27] were used to stain early 
endosomes, nuclei, actin, CD63, FLJ22595 (Arl14/
ARF7), B-actin and HLA-DR, respectively, followed by 
secondary Alexa dye-coupled antibodies (Invitrogen) 
for detection by confocal microscopy. 
Antibodies against human Arl14/Arf7 (ARL14.2) and 
human ARF7EP (used for immune precipitation, 
western blotting and immune fluorescence) were 
produced in rabbits after immunization with 
recombinant GST-Arl14/Arf7 and GST-ARF7EP 
respectively (GST was removed by Thrombin 
cleavage). Anti-HA (12CA5, gift from Dr. H. Ovaa, 
NKI, Amsterdam, NL) was used for co-immune 
precipitation assays. Rabbit anti-human Myo1E (H-
60, Santa Cruz Biotechnology), mouse anti-GST (B14, 
Santa Cruz, sc-138), rabbit anti-mRFP, rabbit anti-GFP 
[28] and anti-HA-PO (Roche, 2013819001) were used 
for detection on Western Blot. Rabbit anti-mRFP was 
also used for immune precipitation.
Flow Cytometry HTS: RNAi Screen Layout
In the primary screen siRNAs (Human siGenome 
siRNA SMARTpool library - Genome, Dharmacon) 
were used to silence human genes in MelJuSo 
cells. In the deconvolution screen, the four siRNA 
duplexes of the smartpool of a potential candidate 
were tested separately. All steps were performed 
in triplicate. MelJuSo untreated and HLA-DM siRNA 
transfected were used as negative and positive 
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control (for CerCLIP), respectively. 
Flow Cytometry HTS: siRNA Transfection
siRNA (50 nM final concentration) was aliquoted 
into 96-well plates (Greiner CELLSTAR® 96-well 
microplates, black, flat bottom) using a liquid 
handling robot (Hamilton ML STAR). Per well, 0.2 
µl DharmaFECT1 (Dharmacon) and 9.8 µl IMDM 
was added to the siRNA, incubated for 20 minutes, 
followed by addition of 4,700 MelJuSo cells using 
a Microplate Dispenser (Matrix WellMate®) and 
culture for three days at 37°C and 5% CO2 before 
analysis.
Flow Cytometry HTS: Analysis
Cells were washed with PBS (Gibco), detached using 
10 μl/well Trypsin-EDTA (Gibco) and incubated with 
5 μg/ml L243-Cy3 and 6.7 μg/ml CerCLIP-Cy5 in 20 
μl/well PBS/2% FCS for 30 minutes at 4°C. Samples 
were diluted to 200 μl with PBS/2% FCS, followed 
by 10 minutes incubation on ice before the mean 
fluorescence intensity (MFI) was determined using 
the BD FACSArray™ Bioanalyzer System (Becton 
Dickinson).
Flow Cytometry HTS: Normalization
Raw flow cytometry data (geometric mean 
fluorescence intensity of each antibody) was 
normalized using the CellHTS2 package of R2.6.0-
based Bioconductor [29]. All data points were 
transformed into z-scores. The average z-score and 
standard deviation of untreated MelJuSo cells were 
calculated. Genes displaying a |z-score|>3 in at least 
two replicates were regarded as ‘candidates’. In the 
deconvolution screen a candidate was considered 
confirmed, when at least two duplexes reproduced 
the phenotype observed in the primary screen.
Microarray Analysis
Human primary monocytes as well as immature and 
mature monocyte-derived DC were isolated and 
differentiated as described [30]. Human primary 
B cells were isolated from peripheral blood and 
activated as described [31]. Detailed protocols 
for RNA isolation, amplification, labeling, and 
hybridization can be found at http://cmf.nki.nl/
download/protocols.html. The Sentrix Human-
6_v.2 BeadChip (Illumina) was used for the whole 
genome gene expression study. The data underwent 
variance stabilizing transformation and robust 
spline normalization. Candidates were considered 
expressed in immune cells with a detection p-value 
of 0.01 or lower. Expression of a gene in at least one 
of five primary cell types led to incorporation in the 
deconvolution screen.
Data on overall gene expression in 79 human tissues 
was obtained from Novartis GNF SymAtlas (http://
biogps.gnf.org). The GC-RMA package processed 
data was LOG-transformed. Expression maxima for 
immune versus normal tissues were determined and 
ranking upon the ratio was performed. Immune-
specific expression threshold was set above a ratio 
of 1.09, which corresponded to that of CIITA.
Quantitative RT-PCR
Messenger RNA was extracted from cells using the 
mRNA Capture Kit (Roche) and reverse transcribed 
into cDNA using the Transcriptor High Fidelity cDNA 
Synthesis Kit (Roche). The qPCR was performed 
using LightCycler® 480 SYBR Green 1 Master (Roche) 
on the LightCycler® 480 Detection System (Roche). 
Primer sequences are available upon request. 
Quantification was performed using the comparative 
CT method (DDCT). The results were expressed 
relative to GAPDH values; normalized to control 
siRNA treated cells and LOG-transformed. In case 
of lentiviral-transduced DC, results were expressed 
relative to 18S rRNA values and normalized to 
shControl treated cells
Confocal Microscopy HTS: 
siRNA Transfection
MelJuSo/HLA-DRB1-GFP/mCherry-GalT2 cells were 
transfected with siRNAs silencing all 276 candidates 
as described above and seeded on μ-Slide 18-well 
plates (flat ibiTreat, Ibidi). Control siRNA and RILP#3 
siRNA, which separates the late endosomal Rab7-
RILP receptor from the dynein motor resulting in 
scattered MHC class II-positive vesicles [32], were 
used as negative and positive control, respectively.
Confocal Microscopy HTS: Analysis
Cells were fixed with PBS/3.75% formaldehyde (free 
from acid, Merck), permeabilized with PBS/0.1% 
TritonX-100 (Sigma) and blocked with PBS/0.5% 
bovine serum albumin (BSA, Sigma). Cells were 
stained with anti-EEA1, goat anti-mouse-Alexa647 
and Hoechst, washed with PBS and covered with 80% 
glycerol (Merck) in PBS. Stained cells were analyzed 
by a Leica AOBS microscope with appropriate filters 
for fluorescence detection. Pictures were taken 
using a HCX PL APO blue corrected 63x 1.32 object. 
Hoechst was excited at l=405nm and detected at 
l=416-470nm; GFP was excited at l=488nm and 
detected at l=500-550nm; mCherry was excited at 
l=561nm and detected at l=570-621 nm; Alexa-647 
was excited at l=633nm and detected at l=642-
742nm.
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Confocal Microscopy HTS: 
CellProfiler and Clustering
Cell image analysis program CellProfiler 1.0.5811, 
as provided by the Broad Institute (Boston, USA), 
was used to extract multiple features from the cells 
in each image [33]. Briefly, nuclei were detected 
as primary objects. From these nuclei the cell was 
detected based on cytosolic background staining. 
EEA1 and MHC class II vesicles and the Golgi were 
detected as primary objects and then assigned 
to a cell containing this object (their parent). The 
membrane area was defined as the area between 
the cell perimeter expanded or shrunken by 10 pixels. 
The CP Analyst 2 program was used to determine the 
minimal number of parameters distinguishing and 
describing phenotypes of interest. During supervised 
machine learning seven bins for MHC class II, three 
for early endosome and five for Golgi features were 
designed. After cross-validation accuracy calculation 
(Figure S4B) six MHC class II parameters, two for 
EEA1 and five for Golgi were selected. All these 
features were z-score normalized in Excel (Table S4). 
The MHC class II related parameters were replicated 
four times and the Golgi related parameters were 
replicated two times to increase their weight in the 
consideration. A similarity matrix was calculated 
and the data were clustered using the Matlab 
Bioinformatics Toolbox. The phylogenetic tree was 
build in Matlab and imported into Cytoscape (2.6.3) 
with the PhyloTree (v.0.1) plug-in. The tree was 
plotted as an organic tree and nodes were coloured 
according to the z-score in the flow cytometry-
based screen. The edge colour was determined by 
the changes in mRNA levels between im and mDCs 
(Table S1). The node size was determined by the 
mDC like phenotype, which is based on microscopy 
data (Table S4). Two bins were created in CP 
Analyst 2: one with wild type cells and one with cells 
resembling an mDC phenotype (MHC class II at the 
cell surface and little MHC class II inside). All cells for 
each candidate were scored for the enrichment of 
the mDC phenotype.
Confocal Microscopy HTS: 
Network Analysis 
Humannet v. 1 [16] was used to predict genes that 
interact with candidate genes (neighbours). Two 
cut-off values were applied to be considered as an 
interacting gene: neighbours have a log-likelihood 
score ≥1 and a |z|≥ 1.645 in the flow cytometry 
screen. All candidates or clusters (with or without 
neighbours) were analyzed for enrichment in Gene 
Ontology terms (Cellular Component). Clusters 
were defined by having a distance of 153.6 from the 
root of the tree and at least 15 genes in the branch. 
Gene Ontology analysis was performed with the 
cytoscape plug-in BiNGO (v.2.3). 
Lentivirus Production
Lentiviruses were produced as described previously 
[34] with following alterations. 293T cells were 
seeded at 3.5x106 per 10 cm dish 24 h before 
transfection in DMEM/7.5% FCS/PS. 293T cells were 
transiently transfected with the viral packaging 
constructs pMDLg/pRRE, pRSV-Rev and pCMV-
VSV-G (ratio 1:1:1) in a ratio of 1:1 with the pLKO.1 
vector harboring the respective shRNA sequence 
using 4 µl Fugene 6 transfection reagent (Roche) 
per µg of DNA. Per 10 cm dish, 2.33 µg of each 
packaging vector, 6.5 µg of pLKO.1 and 0.5 µg of 
pEGFP-C1 [20] (Clontech) were used. After 24 h 
the complete medium was replaced by serum-
free DMEM. After another 24 h of culture, the 
supernatant was harvested and concentrated 100-
fold by ultracentrifugation (Beckman Coultor Rotor 
SW28) at 20,000 rpm for 2 h at room temperature. 
The viral pellet was resuspended in Cellgro medium 
(Cellgenix), snap frozen in liquid nitrogen and stored 
at -80°C. 
Dendritic Cell Transduction 
Human primary monocytes were isolated from 
peripheral blood of healthy volunteers after 
informed consent as described [30], frozen and 
stored in liquid nitrogen. Thawed monocytes were 
plated at one million per well in 12 well plates 
(Falcon) and transduced with lentivirus at a MOI 
of 2 in 1 ml Cellgro medium in the presence of 
4 µg/ml polybrene (Millipore). The medium was 
supplemented with 800 U/ml IL-4 and 1,000 U/
ml GM-CSF (Cellgenix). After 24 h, 1 ml of Cellgro 
plus IL-4 and GM-CSF was added again. Cells were 
cultured for six days at 37°C and 5% CO2 before 
analysis by flow cytometry. Maturation of DC was 
induced at day 5 by adding 10 ng/ml IL-1b, 10 ng/ml 
TNF-a, 1,000 U/ml IL-6 (Cellgenix) and 1 µg/ml PGE2 
(Sigma). For immunofluorescence, DC were seeded 
on μ-Slide 18-well plates (Ibidi) pre-coated with 
20 μg/ml Fibronectin (Invitrogen) and incubated 
for seven hours. Slides were fixed with PBS/3.75% 
formaldehyde and stained with anti-HLA-DR and 
anti-CD63 antibodies, phalloidin and Hoechst. The 
“Measure Correlation” module of CellProfiler was 
used to determine the correlation between CD63 
and MHC class II localisation. Correlation pixel plots 
were determined using the Leica Confocal Software.
Biochemical Experiments: 
Yeast Two-Hybrid Analysis
Arl14/ARf7 Q68L without myristoylation site was 
used as bait in a Yeast Two-Hybrid assay that was 
performed in a skeletal muscle cDNA library at DKFZ, 
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Heidelberg, Germany (information: http://www.
dkfz.de/gpcf/y2h.html). Results are listed in Table 
S7.
Biochemical Experiments: 
Immune Precipitation and Pull-down
Cells (PBMC or MelJuSo) were lysed for 30 min 
in 0.8% NP-40 lysis buffer containing 50 mM NaCl, 
50 mM Tris-HCl pH8.0, 5 mM MgCl2 and phosphatase 
inhibitors (Roche Diagnostics, EDTA free). 
Supernatant after spinning (10 min at max. speed) 
was incubated with GST- or GST-ARF7EP-coupled 
Glutathione Sepharose beads 4G (GE Healthcare) 
or with anti-ARF7EP-, anti-mRFP- and anti-HA-
coated Protein G-Sepharose beads 4 Fast flow (GE 
Healthcare) for one hour. Beads were washed four 
times before addition of Laemmli Sample Buffer 
followed by 5 min incubation at 100°C. Detection of 
co-immune-precipitated proteins was done via SDS-
PAGE followed by western blotting and probing with 
respective antibodies to visualize proteins.
Biochemical Experiments: 
Immune Fluorescence
imDC were seeded on μ-Slide 18-well plates (Ibidi) 
pre-coated with 20 μg/ml Fibronectin (Invitrogen) 
and incubated for seven hours, fixed with 3.7% 
Formaldehyde in PBS or methanol and stained 
for MHC class II, Arl14/Arf7 and B-Actin. MelJuSo 
cells were transfected using FuGENE 6 (Roche 
Diagnostics) with DNA coding for Arl14/Arf7-mCherry 
and GFP-PIP5K1A followed by fixation with 3.7% 
formaldehyde in PBS two days post-transfection and 
staining for MHC class II.
Biochemical Experiments: GEF Assay
Ten μM GST-ARF6, GST-ARL14 or GST in loading buffer 
(1 mM EDTA, 4 mM MgCl2, 50 mM HEPES pH7.6, 
1 mM DTT) were incubated with 100 μM MBP-SEC7 
domain of CYTH1 or PSD4 in loading buffer. Then, 
3.3 μM)  [α-32P]GTP (>5000 Ci/mmol) was added 
and incubated at 30ºC for 20 min. The reactions were 
stopped by adding 500 μl cold stop buffer (100 mM 
NaCl, 10 mM MgCl2, 20 mM HEPES pH7.6) and 20 μl 
Glutathione beads. The beads were washed five 
times with stop buffer to remove unbound [α-32P]
GTP and measured by liquid scintillation counting. 
Free GST was taken as background and subtracted 
from all measurement values.
Biochemical Experiments: 
Lipid Binding Assay
HEK293T cells transiently overexpressing GST-
PH-PH (PSD4) were harvested in 0.1% NP-40 lysis 
buffer, containing 50 mM Tris-Cl (pH7.4), 100 mM 
NaCl, 5 mM MgCl2 and protease inhibitors. Cells 
were frozen at -80°C and thawed again followed 
by sonication. Lysis was extended for 45 min at 4°C. 
The supernatant after centrifugation was added to 
Glutathione Sepharose beads 4B to isolate GST-PH-
PH (PSD4) from the lysate. Beads were washed two 
times, GST-PH-PH (PSD4) was eluted from beads 
using 100 mM Glutathione and used for the Lipid 
Binding assay. 
PIP-StripsTM (tebu-bio) were blocked in PBS 
containing 3% fatty acid free BSA (Sigma # A-7030). 
The PIP-Strip was incubated with GST-PH-PH 
(PSD4) and the positive control (PLC-d1 PH domain, 
PI(4,5)P2 GRIPTM, tebu-bio) overnight. Binding to 
phosphoinositides was visualized by incubation with 
anti-GST antibody (B-14, Sc138 from Santa Cruz).
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Figure S1 | Deconvolution of Genes known to affect the MHC Class II Pathway. Relates to Figure 2 (Chapter 1)
This figure explains the absence of genes known to be involved in the MHC class II pathway from our candidate 
list. Orange box: |z-score|<1; gray box: |z|<3. Representative, non-toxic siRNA duplexes are shown.
A | HLA-DM consists of an a and b chain and acts as a chaperone for MHC class II loading. While HLA-DMB showed 
a significant effect, HLA-DMA did not. For HLA-DMB, three siRNA duplexes show upregulation of CerCLIP labelling, 
two of which by a |z|>3 (our threshold). When silencing HLA-DMA only two duplexes gave an effect just below 
our threshold. 
B | Some siRNA duplexes against HSPA5 (BiP, a chaperone in the ER that binds newly synthesized MHC class II) 
or CCNT1/CCNT2 (Cyclin T1/T2, both components of the transcriptional elongation complex PTEFb, which binds 
CIITA to turn on MHC class II transcription) showed a decrease in L243, but their effect was below the threshold. 
C | Subunits of AP2 (Adaptor Protein 2 complex which is involved in the trafficking of MHC class II molecules) were 
not identified in the screen because silencing of individual subunits does not influence L243 or CerCLIP levels.  
D | CIITA showed a pronounced effect, but the other factors involved in MHC class II transcription like NFY, RFX 
and CREB did not. As the deconvolution shows, silencing of these genes decreases L243 levels, but only with a 
z-score below our threshold of |z|>3.
E | Invariant chain (CD74) silencing also decreased L243 levels, but again below the threshold. No effect on CerCLIP 
levels was found. 
46
Figure S2 | Pathway Analysis of Targets grouped according to the Effects observed in the Primary Screen. 
Relates to Figure 2 (Chapter 1)
The 276 targets were grouped according to their effect on MHC class II at the cell surface. These four clusters (L243 
up, L243 down, CerCLIP up and L243/CerCLIP up) were analyzed using the open source database and network 
program String (A) and the Ingenuity Pathways Analysis (IPA) program (B), resulting in networks summarized in 
this figure. Candidates identified in the screen are highlighted in pink in IPA-derived networks.
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Figure S3 | Higher Order Control of the transcriptional Network. Relates to Figure 3 (Chapter 1)
Based on literature and experimental data (red box), factors interacting with candidates involved in 
transcriptional control and pathways were annotated in more general terms. Numbers correspond to 
Supplemental References [1-15].
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Figure S4 | Confocal Microscopy Image Analysis and ‘Supervised Machine Learning’. Relates to Figure 4 
A | MelJuSo/HLA-DRB1-GFP (green)/mCherry-GalT2 (red) cells were transfected with siRNAs silencing all 276 
candidates and seeded on μ-Slide 18-well plates. After three days cells were stained for early endosomes (blue). 
On representative slide is shown. High resolution images of all slides can be found on http://www.neefjeslab.nl/. 
B | Confocal images after gene silencing were analyzed by Cell Profiler. Prominent phenotypes were identified 
and the Cross-Validation Accuracy for MHC class II parameters after supervised machine learning in CP Analyst 2 
was determined. Accuracy to distinguish defined phenotypes does not increase when more than six parameters 
are used.
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Figure S6 | The connectivity targets measured by the 
Area Under the Receiver Operating Characteristic 
(ROC) Curve (AUC) determined by program 
humannet v.1. Relates to Figure 5 (Chapter 1)
With an AUC of 0.6175 many of the connected genes 
(neighbours) are highly expected to interact in reality. 
Neighbours with a log-likelihood score ≥1 and a 
|z| ≥1.645 (p<0.1) in our original flow cytometry-based 
screen were considered for further analysis (Table S6). 
Figure S5 | Hierarchical Clustering of Microscopy Data. Relates to Figure 4C and 5 (Chapter 1)
The (dis)similarity between phenotypes upon knockdown of different genes is represented in this hierarchical 
clustering. A distance of 153.6 to the root of the tree was arbitrarily chosen as a cut-off value. Branches with more 
than 14 genes were used for further analysis (Figure 4C, Chapter 1).
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Figure S7 | Effect of selected Candidates on the Redistribution of MHC Class II in Dendritic Cells. Relates to 
Figure 6  (Chapter 1) 
Monocytes were transduced with lentiviruses encoding shRNAs directed against seven candidate genes (four 
shRNA constructs per gene). After six days, imDCs generated from the transduced monocytes were analysed. 
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Figure S7 | continued 
A | Fold increase in CLIP-loaded MHC class II (CerCLIP) or general MHC II levels as detected by flow cytometry 
of three donors normalized to cells transduced with empty viral particles is shown. Four non-targeting shRNA 
sequences were used as shControl. HLA-DMB represents a positive control for the increase of CerCLIP, whereas 
L243 levels on mDCs can be considered as maximum. Shown is the 10-90 percentile with median value.
B | Representative images of all candidates silenced by lentiviral transduction of imDC, which confirmed their 
flow cytometry phenotype of MelJuSo cells in imDCs are shown. Confocal images stained for nucleus, actin 
(Phalloidin), CD63 and MHC class II were taken. The normalized correlation coefficient of CD63 and MHC class II is 
stated in the merged image (average of shControl treated DCs equals 1, average of mDCs equals 0). Bar = 10μm
C | The correlation between CD63 and MHC class II was quantified using Cell Profiler. Ten images were taken per 
construct per donor. Correlation coefficients were normalised to shControl treated cells. Mean of all donors ± 
s.e.m. is shown for one out of four constructs. The two controls (HLA-DMB and MHC2TA) show no significant 
effect, whereas all tested candidates (except PIK3R2) show a significant correlation towards a mature DC 
phenotype in their MHC class II distribution. 
A, C | * p<0.05, ** p<0.01, *** p<0.0001, Student's t test.
Supplemental Tables 1-7 
available online at http://dx.doi.org/doi:10.1016/j.
cell.2011.03.023 
Table S1 | Expression of Candidates in human primary 
Immune Cells and Tissues, Relates to Figure 1 and 2 
(Chapter 1)
mRNA of five different human primary immune cells 
(unstimulated and CD40L-activated B cells, primary 
monocytes, immature and mature monocyte-derived 
DC) was isolated and submitted to microarray 
analysis to investigate the expression levels of the 
candidates from the primary siRNA screen. The 
cells were characterized by flow cytometry for their 
lineage, MHC class II expression and activation status 
(data not shown). This table represents the average 
signal and the detection p-value of the microarray 
analysis. Probes for some of the hits were absent 
from the array as indicated at the bottom of the 
table. Gene expression data for 79 human tissues 
was retrieved from the GNF SymAtlas database. 
The detection signals are represented in this table 
divided into immune and non-immune tissues. The 
maxima for each group are determined and a ratio 
of 1.09 (as for CIITA) or higher is considered ‘immune 
tissue-specific’. Sixty-nine hits fall into this group 
(highlighted in green).
Table S2 | Summary of the Results after Deconvolution, 
Relates to Figure 1 and 2 (Chapter 1)
The primary screen was performed using a pool of 
four siRNA duplexes per gene from a Dharmacon 
library. For deconvolution, the candidates were 
silenced using the four individual duplexes. This table 
summarizes the measured effects of each annotated 
siRNA pool and the number of duplexes confirming 
the phenotype in the pool of four siRNAs (for both 
L243 and CerCLIP, separately). The function and the 
cellular localization of the candidates were extracted 
from the Ingenuity Pathways Analysis program.
Table S3 | Description of Factors acting in a 
Transcriptional Network on the MHC Class II Locus 
identified by HTS qPCR, Relates to Figure 3 (Chapter 
1)
Information based on published literature.
Table S4 | Summary of HTS Microscopy Results after 
Cell Profiler Calculation and CP Analyst 2 classification 
including mDC Phenotype Enrichment Score, Relates 
to Figure 4 (Chapter 1)
Six confocal microscopy pictures for each siRNA 
silencing situation were analyzed using Cell Profiler. 
After manual selection for prominent phenotypes 
and ‘supervised machine learning’, the most 
descriptive parameters for these phenotypes were 
determined. Per annotated gene, the values for the 
selected parameters used for clustering are listed in 
this table. Two bins were created in CPanalyst. One 
with wild type cells and one with cells resembling an 
mDC phenotype (MHC class II at the cell surface and 
little MHC class II inside). All cells for each candidate 
were scored for the presence of these two 
phenotypes. The p value for the mDC phenotype is 
indicated.
 
Table S5 | Gene Ontology Analysis of all our Candidate 
Genes. Relates to Figure 5 (Chapter 1)
The p value for ‘cellular component’ terms that are 
enriched in our dataset are given. The p values for 
‘cellular component’ terms that are enriched in our 
dataset (extended with their neighbours) are given.  
Table S6 |  Genes connected to the Candidate Genes 
(Neighbours). Relates to Figure 5 (Chapter 1)
Humannet v. 1 was used to predict genes (Entrez 
Gene ID) that are likely to interact with candidate 
genes [16]. For each of the four clusters potentially 
interacting genes are indicated with the number 
1. Each potentially interacting gene has at least a 
minimal absolute z-score of 1.645 (p=0.1) in the 
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genome wide flow cytometry screen for effects on 
L243 and/or CerCLIP.  
Table S7 | Proteins binding to Arl14 as detected in 
Yeast Two-Hybrid Assay. Relates to Figure 7 (Chapter 
1)
All different preys picked up in Yeast Two-Hybrid 
assay with constitutive Arl14 used as bait. C11orf46, 
shaded in green and called ARF7EP in this study, was 
picked up 10 times. Three other interacting proteins 
(yellow) were found only once. The false positive 
preys (promiscuous preys and fragments from the 3’ 
UTR) are depicted in orange.
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MHC class II molecules (MHC-II) present antigenic 
fragments acquired in the endocytic route to the 
immune system for recognition and activation 
of CD4+ T cells. This ignites a series of immune 
responses. MHC-II strongly correlates to most 
autoimmune diseases. Understanding the biology 
of MHC-II is therefore expected to translate into 
novel means of autoimmunity control or immune 
response improvement. Although the basic cell 
biology of MHC-II antigen presentation is well 
understood, many novel aspects have been 
uncovered in recent years including means of 
antigen delivery, preparation for MHC-II loading, 
transport processes and vaccination strategies. 
We will discuss past, present and future of these 
insights into the biology of MHC-II. 
Introduction
Like all glycoproteins, MHC-II α- and β-chains are 
synthesized and assembled in the ER. Here they 
associate with Invariant Chain (Ii), which prevents 
premature binding of peptides to the MHC-II 
peptide-binding-groove and promotes exit from the 
ER and transport through the Golgi. The Ii contains 
a dileucine-based motif recognized by Adaptor 
Protein 2 (AP2) or AP3 complexes [1-3]. This motif 
is required for sorting at the Trans-Golgi-Network 
(TGN) and plasma membrane (PM) towards the 
MHC-II containing compartments (MIIC) [4-6] 
(pathway components discussed in this chapter 
are summarized in Figure 1). In the MIIC, residing 
proteases degrade antigens and Ii with the exception 
of a small fragment (called CLIP), protected by its 
embedding in the peptide-binding-groove of MHC-II. 
The CLIP fragment is exchanged for new (antigenic) 
peptides catalyzed by a unique and dedicated 
chaperone DM (H2-M in mice, HLA-DM in humans). 
DM is a MHC-II look-alike that interacts with MHC-
II, stabilizing it in a state devoid of peptides, which 
would otherwise be prone to aggregation and 
degradation [7]. The peptide exchange reaction is 
stimulated by acidic pH and occurs in subdomains of 
the MIIC [8]. 
Probably, the MIIC does not have a ‘Quality Control 
System’ like the ER that allows exit of properly 
folded and assembled proteins only. The expression 
of MHC-II/CLIP complexes at the PM in the absence 
of DM illustrates this point. The MIIC moves to the 
PM for surface deposition of MHC-II, most likely after 
a certain intracellular residency time. In addition, 
MHC-II-bearing exosomes might be released 
conveying immunological information beyond the 
initial antigen presenting cell (APC).   
The biology of antigen presentation by MHC-II has 
been studied for over 20 years by many groups and 
has yielded a fairly consistent view on the molecular 
basis underlying the successful acquisition of peptide 
fragments in the endocytic pathway for presentation 
at the PM. In general terms, assembly of MHC-II, 
their preparation for peptide loading, the generation 
of peptide fragments and transport processes are 
understood at almost atomic resolution. Yet many 
new findings complicate the initially simple biology. 
We will describe the state-of-art understanding 
based on recent insights. We will follow the general 
route of MHC-II from its birth in the endoplasmic 
reticulum (ER), through the endosomal pathway to 
the PM, exosomes and to their degradation. Along 
this path, we will not only describe new biological 
findings but also their application as new tools to 
manipulate MHC-II antigen presentation.
Delivery of Antigens to MIIC 
Uptake of exogenous antigens can occur via several 
routes, reviewed by [9]. Each immune cell type has 
found its own one. B cells are poorly phagocytic, 
but they can take up IgM-coated Salmonella in 
a B cell receptor (BCR)-mediated pathway for 
antigen presentation in context of MHC-II [10]. The 
effectiveness of antigen presentation in dendritic 
cells (DC) depends on the cells’ origin, maturation-
stimulus and route of antigen uptake. These 
observations aid the understanding of immune 
response initiation and designing of vaccination 
strategies using DC and activated monocytes [11]. 
Recently it has been shown that DC continue 
to accumulate antigens via DEC205-mediated 
endocytosis and FcγR-mediated phagocytosis 
even after maturation, the latter involving the 
PIP5K isoforms a and γ [12]. Freshly synthesized or 
recycled MHC-II is loaded with the newly acquired 
antigens [13]. Endocytosis of DEC205 antibody-
coupled peptides results in efficient uptake and 
delivery to the MIIC. This strategy has been applied 
to DC of melanoma patients resulting in effective 
peptide presentation. The stimulatory capacity of 
those DC was maintained after cryopreservation, 
which makes it an interesting approach for cancer 
immune therapy [14]. Antigen acquisition targeting 
Ig, Fc, complement or lectin receptors appears to 
be a feasible strategy to improve MHC-II antigen 
presentation and immune response outcome.
How cytosolic antigens reach MHC-II and why, 
although abundant, they only represent a minor 
fraction of all presented peptides (MHC ligand 
database; http://www.syfpeithi.de) [15], was 
unclear for a long time. Autophagy is a cell biological 
solution for the entry of cytosolic material into the 
lysosome. Membranes form and encapsulate parts 
of the cytosol forming autophagosomes, a process 
requiring ATG5 [16]. As reviewed by Nedjic and 
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colleagues, cortical thymic epithelial cells contain 
many autophagosomes [17] generating an array of 
different peptides, thereby shaping the self-tolerant 
T cell repertoire, as became clear from studies in 
ATG5-/- thymi [18]. ATG5-/- DCs are defective in 
phagosome-to-lysosome fusion, thereby inhibiting 
processing and presentation of extracellular 
microbial antigens [19]. Particular proteins are more 
selectively targeted to the autophagosome when 
coupled to ATG8/LC3, which in turn enhances their 
MHC-II presentation rate [20].
Antigen Processing in the MIIC
Antigens have to be unfolded for efficient 
degradation and peptide formation. One recently 
identified endosomal protein (called GILT) oxidizes 
disulfide linkages found in many extracellular 
proteins [21] and is essential for the presentation of 
a series of antigens [22]. GILT activity can strongly 
enhance antigen presentation of a melanoma 
antigen [23]. Acidic pH and chaperones might 
participate in further unfolding before substrates are 
processed by resident proteases. Many of these are 
cysteine proteases of the cathepsin family and are 
involved in inflammation, autoimmunity and cancer 
(reviewed by [24] and [25]). Nowadays, various 
cathepsin inhibitors are tested in primary immune 
cells as tools for immune response modulation in 
autoimmune diseases (Table 1). 
 
Manipulating Peptide Loading of MHC-II 
in the MIIC
DM can stably associate with a unique co-chaperone 
DO (H2-O in mice, HLA-DO in humans), which is 
fairly selectively expressed in immature B cells and 
certain DC types. DO is also an MHC-II look-alike 
and functions as a pH sensor that alters the pH 
optimum of DM-mediated peptide loading of MHC-
II to more acidic conditions and thereby changes 
the peptide repertoire presented by MHC-II [26]. 
In fact, presentation of many peptides is prevented 
by DO yielding more MHC-II/CLIP expression at the 
PM. Consequently, T cell help for B cells is reduced 
when DO is expressed [27]. DO may skew the DM 
support of MHC-II peptide loading to late and more 
Figure 1 | The Transport Route of MHC Class II
After Ii binding in the ER, MHC-II is transported to the MIIC either directly (A) or via the PM (B) due to a dileucin 
motif in the associated Ii. In the MIIC, the Ii is degraded and the remaining CLIP fragment is exchanged for a new 
peptide in a process chaperoned by DM. After loading MHC-II is transported to the PM (C) or secreted on exosomes 
(D). MHC-II, MHC class II molecule; Ii, Invariant chain; AP2, Adaptor Protein 2; GILT, Gamma-interferon-inducible 
lysosomal thiol reductase precursor; DM, HLA-DM; DO, HLA-DO; ESCRT, Endosomal Sorting Complex Required for 
Transport; ATG, Autophagy related; ORP1L, oxysterol-binding protein; RILP, Rab7-interacting lysosomal protein; 
SLP4, Synaptotagmin-like protein 4;  EE, early endosome; MIIC, MHC-II containing compartment.
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acidic endosomes, which are preferentially accessed 
by antigens taken up by BCR-mediated endocytosis. 
It is believed that this is preventing autoimmune 
responses by controlling the activation of B cells 
present peptides corresponding to antigens taken 
up by the BCR [26]. Indeed, NOD mice (susceptible to 
develop Type 1 Diabetes) overexpressing DO present 
an altered self-peptide repertoire which prevents 
activation of diabetogenic T cells and hence diabetes 
onset. DO possibly shapes the overall MHC-II self-
peptide repertoire to improve T cell tolerance [28].
Small molecules affecting peptide loading of MHC-II 
can be of interest for autoimmunity (inhibitors) or 
vaccines (accelerators). Amines like chloroquine are 
known to neutralize MIIC and inhibit peptide loading 
[29]. Protease inhibitors affect the degradation of 
Ii or antigen (Table 1). More recently, a family of 
compounds was described to accelerate MHC-II 
peptide loading in vitro, without the help of DM, 
and promote peptide binding in APC in vivo [30]. 
Altered Peptide Ligands (APLs) are built to be more 
protease resistant, to reach the MIIC more easily and 
to be presented more efficiently (for review [31]). 
Manipulating MHC-II function becomes a realistic 
option to direct immune responses.
A topological Problem: Retrofusion or 
Exosomes?
MIIC consist of a limiting (outer) membrane and 
luminal vesicles (LV). It is still under debate whether 
LV are a stable structure or dynamically form and 
disappear again through retrofusion with the 
limiting membrane. The subdomains of MIIC differ. 
The LV contain tetraspanin molecules, cholesterol 
and the lipid LBPA, while the limiting membrane 
concentrates molecules like the GTPase RAB7, LAMP 
and the cholesterol transporter ABCA1. MHC-II and 
DM are detected on both membranes. Studies 
have shown that the LV are their preferred site of 
interaction [8]. MHC-II/DM complexes might be 
stabilized through association with the tetraspanin 
web (made of CD63, CD82 and others) [32, 33]. The 
interaction of MHC-II and DM on LV has interesting 
consequences for pathogens in phagosomes, such 
as Salmonella. Phagosomes do not have LV and MHC-
II located at their limiting membrane fails to acquire 
peptides due to lack of DM support, therefore 
allowing immune escape of intracellular bacteria [8]. 
The LV can be secreted to the extracellular 
environment as exosomes. Mass spectrometry 
analysis of protein and lipid content of purified 
B cell exosomes verifies their origin from LV of 
MIIC (albeit at a considerably higher resolution) 
[34, 35]. The turn-over of MIIC takes only hours, 
whereas the half-life of MHC-II (8-48 hours) [36] or 
CD63 (2 days) [37] is considerably longer implying 
that the proteins have to be recovered from the 
LV not to be lost through exosome secretion. To 
our opinion, exosomes are the result of inefficient 
retrofusion of the LV to the limiting membrane of 
MIIC before fusion with the PM. How the process of 
retrofusion occurs is unclear. Alternatively LV might 
be stable nanocomplexes that survive necrosis, 
like proteasome and ribosome, which can be easily 
detected in tissue culture medium and body fluids 
[38]. Nonetheless, exosomes can have interesting 
functions.
Function and Application of MHC-II-
bearing Exosomes
Exosomes are shed by almost all cell types and differ 
in content accordingly (reviewed in [39]). Exosomes 
contain cytosol. How the cytosolic contents are 
selected, is unknown. Exosomes resemble their 
cell of origin’s topology and expose proteins like 
MHC-I and -II, CD1, tetraspanins, costimulatory 
molecules and adhesion molecules, such as ICAM-1. 
In fact, MHC-II-bearing exosomes can be considered 
‘nano immune cells’ and have been found to exert 
both immune stimulatory and regulatory functions 
in intercellular communication (Figure 2). When shed 
by DC, exosomes can present antigen in context of 
MHC-II to activated T cells or T cell lines directly [40] 
or indirectly to naïve T cells when recaptured by 
recipient APCs [41]. Such recapture requires binding 
to host membranes mediated by LFA-1 and its ligand 
Table 1 | Recently developed Cathepsin Inhibitors and their Effects
Inhibitor Target Effect
ZRLR Cathepsin B Enhances presentation of Tetanus Toxin-C (TTC) fragment to T-cells [70].
CatG Inhibitor Cathepsin G
Reduces processing of TTC and Hemagglutenin (HA) peptides and their 
presentation to CD4+ T-cells [71].
Suc-VPF Cathepsin G
Reduces processing of TTC and Hemagglutenin (HA) peptides and their 
presentation to CD4+ T-cells [71].
Compound 47 Cathepsin S Inhibits processing of invariant chain [72, 73].
CAA0225 Cathepsin L Involved in degradation of autophagosomal membrane markers [74].
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the PM [53]. How movement to the PM by kinesin 
motors is controlled, is unclear. Finally, MIIC have to 
fuse to the PM which probably requires the activity 
of RAB27A and its effector SLP4. This is directly 
correlated to the secretion of exosomes in HeLa cells 
[54]. Sorting of MHC-II to exosomes was shown to be 
ubiquitination-independent. Forced ubiquitination 
of MHC-II induces a decrease of MHC-II at the PM, 
but no enrichment on exosomes [55]. In the study 
of Buschow et al. it was shown that coculturing of 
DC with cognate T cells induced DC activation and 
exosome secretion independent of ubiquitination 
[56]. Although parts of MHC-II transport control 
are understood in detail, regulation of most other 
steps remains obscure and may be uncovered in the 
coming years.
 
Finally at the PM; Internalization and 
Recycling
It has been known for some time that the half-life 
of MHC-II at the PM is cell type dependent. When 
MHC-II associated to Ii arrives at the PM, they are 
internalized because of the dileucine motif in the 
Ii [57]. MHC-II, devoid of Ii, does not contain such 
internalization motifs and remains at the PM. Still, 
MHC-II has a longer lifespan on B cells than on 
monocytes, which is even further reduced following 
IL-10 exposure [36]. IL-10 upregulates a ubiquitin 
ligase called MARCH1, which modifies MHC-II and 
reduces its half-life [58]. The downregulation of 
MARCH1 expression in mature DC compared to 
immature DC corresponds to an increase in MHC-
II half-life at the PM of the former [59]  (Figure 3). 
Viruses and bacteria can use the ubiquitination 
machinery to manipulate MHC expression [60]. 
ICAM-1 on the exosome [42, 43]. Tumors are known 
to shed exosomes. Szajnik et al. have recently 
defined a new escape mechanism in cancer based on 
the activation of regulatory T cells (Tregs) in tumor 
patients [44]. Whether exosomes enter the recipient 
cells’ MIIC for retrofusion, fuse with the PM or act 
as ‘nano immune cells’ is a fascinating subject and 
still unclear. 
 The immunogenetic potential of DC-derived 
exosomes has been demonstrated for vaccines 
against Leishmania major [45] and as cancer therapies 
in vivo in the past (reviewed in [46]). An alternative 
to the isolation of exosomes from patient-derived 
DCs might be the generation of artificial exosomes 
[47]. The advantage of exosome-based vaccines 
over other vaccination strategies remains to be 
proven in side by side comparative studies.
And out we go… MHC-II Transport to the 
Plasma Membrane
MHC-II is transported from the MIIC to the PM 
along microtubules in at least two different ways; 
1. MIIC can move to the PM followed by fusion of 
the limiting membrane with the PM [48] 2. Tubules 
extend from MIIC towards the PM [49, 50],  and 
vesicles may bud off to fuse with the PM [51]. This 
has been detected mainly in activated DC and not 
in other cell types. Close inspection of both routes 
shows that MIIC move in a bidirectional and stop-
and-go manner by the activities of the dynein and 
kinesin motor proteins. Cholesterol, shown to 
influence MHC-II PM expression [52], controls the 
RAB7 effector ORP1L that controls RILP and the 
dynein motor. High cholesterol prevents the release 
of the dynein motor, inhibiting MIIC delivery to 
Figure 2 | Exosome Functions 
Exosomes derived from dendritic cells can exert 
immune activating functions. Naïve T cells can be 
primed in an antigen-specific manner. Exosomes 
derived from tumor cells can exhibit immune 
regulatory functions by activating regulatory T cells. 
ICAM-1, intercellular adhesion molecule 1; LFA-1, 
lymphocyte function-associated antigen 1; TCR, T cell 
receptor; IL-10, interleukin-10; TGFb, tumor growth 
factor b; TAA, tumor associated antigen
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Conclusion
The cell biology of MHC-II has been studied for over 
two decades starting with the work of Unanue 
et al., who demonstrated inhibition of antigen 
presentation by chloroquine [29]. Since then many 
steps have been solved at the cell biological and 
atomic level. MHC-II antigen presentation comprises 
of processes like transport via various endosomal 
compartments, synthesis, ubiquitination and 
degradation. The routes of MHC-II involve many 
targets for manipulation to affect MHC-II expression 
and peptide loading, which is relevant for disease 
states like autoimmunity, infection and cancer.  
Salmonella typhimurium inhibits PM expression of 
MHC-II in DCs by ubiquitinating the HLA-DRb chain 
using bacterial type III secretion system effectors 
rather than MARCH1 to directly modify HLA-DRb [61-
63]. HIV-Nef affects MHC-II expression and peptide 
loading by a different mechanism. The Nef protein 
triggers MHC-II internalization in a cholesterol 
dependent and clathrin- and dynamin-independent 
manner [64], but the exact details are unknown. 
Upon internalization MHC-II has two options: 1. 
return to the PM prior to or after peptide exchange 
or 2. become degraded. In recycling endosomes, 
MHC-II can be loaded with new peptides in a DM-
dependent [65] or independent manner [66] and 
transported back to the PM. This process involves at 
least ARF6, RAB35 and EHD1 [67]. Uptake of antigens 
in early endosomal compartments (that are relatively 
poor in proteases [68]) will allow presentation of 
other peptides than those generated in MIIC, hence 
broadening the peptide repertoire for the good or 
bad, which is unpredictable. Where MHC-II ends-up, 
when recycling fails, remains unclear. The reductase 
GILT (breaking disulfide bonds in the Ig domains 
of MHC-II) and cathepsins, such as cathepsin G, 
which degrades the MHC-II b-chain in vitro [69], 
might be involved. How the life of MHC-II is exactly 
terminated, however, remains an open question. 
Clearly, MHC-II is a cannibal presenting fragments of 
its deceased brothers or sisters. In fact, such MHC-II 
derived peptides are major constituents of the MHC-
II peptide repertoire.
Figure 3 | MHC Class II Internalization, Recycling and Degradation
At the PM of immature DC, MHC-II can be ubiquitinated by MARCH1 and is transported via ARF6/RAB35/EHD1-
positive tubular structures towards Recycling Endosomes (RE). After internalization, MHC-II may return to the 
PM (A) or proceed to degradation (B). In mature DC, MARCH1 expression is downregulated, resulting in decreased 
internalization, a long cell surface half-life and elongated presentation of antigen. PM, plasma membrane
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Professional antigen presenting cells, such 
as dendritic cells, are effective in activating T 
lymphocytes due to their unique ability to present 
antigens in the context of both MHC class I and II 
molecules. After successful loading with antigenic 
peptides MHC class II molecules traffic from the 
late endosomal loading compartment to the plasma 
membrane to exert their function of presenting 
peptides to T helper lymphocytes. Various 
processes play a role in this event, which are only 
partly understood to date. The following protocols 
demonstrate a strategy of how to integrate 
high throughput datasets to select candidates 
possibly involved in MHC class II transport for 
in depth studies. A combination of proteomics, 
RNAinterference and biochemical experimentation 
can uncover novel pathways regulating transport 
processes in primary dendritic cells.
1. Introduction
Dendritic cells (DC) are professional antigen 
presenting cells (APC) that regulate the adaptive 
immune response by stimulating naïve T cells (see [1] 
for review). Expression of peptide-loaded MHC class 
II molecules at the cell surface is the result of tightly 
regulated transport processes from late endosomal 
compartments (called MIIC [2-4]), where antigen 
loading takes place. For a detailed description of 
the MHC class II pathway see [5, 6]. In DC MHC 
class II transport to the cell surface is enhanced 
when danger signals are encountered [7, 8]. Various 
intracellular proteins have been associated with 
this process, such as iNOS and caspases [9]. The 
ubiquitin ligase MARCH1 modifies MHC class II in 
human immature DC (imDC) [10, 11], clathrin and AP2 
orchestrate endocytosis [12], and cystatins regulate 
cathepsin activities [13]. Despite these findings, 
many open questions remain when it comes to the 
control of MHC class II transport in DC. For example, 
which motors are involved in MIIC transport? Little 
is known about this. Myosin II has been reported 
to interact with invariant chain (Ii) to control MHC 
class II transport in B cells [14]. Another actin-based 
motor, myosin 1E, has been recently implicated 
to be responsible for the positioning of MHC class 
II-positive vesicles in DC [15]. The dynein motor is 
recruited to MIIC via the small GTPase Rab7 [16].
One way of identifying new players in the MHC 
class II transport route is to select candidates 
following an RNAinterference (RNAi) screen 
and other high throughput cell biological assays. 
Gene knockdown is achieved by introducing 
small interfering RNA molecules (siRNA) or short 
hairpin RNA (shRNA) which are provided as either 
genome-wide or specialized libraries (kinases, 
phosphatases, G-protein coupled receptors, etc.). 
The resulting candidates can then be tested in 
smaller scale in primary DC. RNAi screens can be 
performed by microscopy as well as flow cytometry 
when appropriate antibodies are available. For a 
comparison of the two methods see Table 1. For 
the RNAi screen described here, changes in cell 
surface expression of MHC class II detected by flow 
cytometry serves as a primary read-out. In general, 
a robust read-out is essential. Negative and positive 
controls are required. See [17] for a review on tips 
and tricks of RNAi screening. Secondary screens 
may subsequently be used to cluster candidates into 
phenotypically similar pathways, which is essential 
for creating new biology.
Primary immune cells are often unsuitable for 
screening. They are limited in number, difficult to 
manipulate and prone to differentiate. Cell lines 
can serve as substitutes. For a list of MHC class II-
positive cell lines see Table 2. For any of these cell 
lines, functionality and transfection efficiency need 
to be determined and optimized before large scale 
screening activities. In some cases activation with 
cytokines is required for efficient antigen processing 
and presentation. 
Following the primary screen, microarray or deep 
sequencing studies on APCs provide information 
whether genes that influence MHC class II surface 
levels in cell lines are expressed in primary cells. 
The model cell line may be used for further high 
throughput (HT) experimentation: (1) Quantitative 
RT-PCR (qRT-PCR) following silencing of genes 
identified in the primary screen reveals whether 
the transcription rate of the MHC locus is altered. 
(2) Immunofluorescence and confocal microscopy 
provide vital information on alterations of the 
intracellular MHC class II distribution. The large 
Table 1 | Characteristics of Flow Cytometry versus Microscopy
Flow Cytometry Microscopy
Readout Intracellular or PM Mainly intracellular
Analysis Simple Complex, software programs needed
Quantity Many data points (cells) Few data points
Detail Little insight Precise localization, many features detected
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amount of images generated can be analyzed and 
clustered based on similarity using open software 
programs such as Cell Profiler and CP Analyst [18, 19]. 
To select candidates for in-depth follow-up studies, 
stringent criteria must be set. When addressing the 
question of what regulates MHC class II transport in 
DC, the following key points need to be considered. 
Silencing a gene that is a positive regulator of 
transport might result in reduced MHC class II levels 
at the plasma membrane. Knocking down a negative 
regulator, on the other hand, will result in higher cell 
surface expression levels. If this regulator is involved 
in the maturation-induced outward transport of 
MHC class II, its expression level might be lower in 
mature (m)DC compared to imDC, information that 
can be deduced from the gene expression data set. 
Finally, the intracellular distribution of MHC class 
II might be altered after silencing. For an example 
of HT data set integration and candidate selection 
strategy see [15].
The protocols described below are dedicated at 
how candidates selected from HT data sets can be 
validated and investigated in DC. First, the effects 
of silencing the candidate genes observed in the 
screen need to be confirmed in the primary immune 
cell. Lentiviral transduction is an efficient tool for the 
introduction of shRNA into human monocytes which 
can then be differentiated into imDC. In principle, 
such viral particles can also be used to introduce 
overexpression constructs. Once candidates that 
alter the transport of MHC class II are confirmed 
and changes of MHC class II gene transcription 
are excluded, the search for interaction partners/
effectors can begin. Different methods can be applied 
for this purpose depending on which type of protein 
is selected. Yeast Two Hybrid (Y2H) technologies 
have been proven to be useful when looking for 
effectors of small GTPases. In our experience, for 
effector molecules of other protein classes (e.g. 
scaffold proteins) GST pulldown might be a more 
suitable method [20]. Kinases in general exceed very 
short lived interactions, which are difficult to detect 
in either assay. Any interaction identified using 
these methods needs to be confirmed by alternative 
methods, e.g. coimmunoprecipitation. All these 
techniques and considerations are required to build 
new pathways from high content screening data.
An RNAi screen only helps identifying potential 
candidate genes controlling a biological 
phenomenon. To understand the cell biology at a 
high content level, secondary HT screens can be 
applied. Subsequently, these are integrated with 
other datasets such as those from microarray, yeast 
two-hybrid and proteomics. When properly done, 
new pathways can be generated allowing definition 
of the control of MHC class II transport in primary 
DC.
2. Materials
2.1 Lentiviral Transduction of DC 
• Human monocytes isolated from peripheral 
blood 
• Cell line for lentivirus production (e.g. human 
293T cells)
• Media and supplements: Cellgro medium 
(Cellgenix) or other medium for serumfree 
cultivation of dendritic cells, DMEM (GIBCO), 
fetal calf serum (FCS, Greiner), Phosphate-
Buffered Saline (PBS, dissolve 1 tablet in 500 ml 
of distilled water, GIBCO) pH 7.4, trypsine-EDTA 
(GIBCO), IL-4 (Cellgenix), GM-CSF (Cellgenix), 
maturation trigger such as lipopolysaccharide 
LPS (Invivogen) and IFN-γ (Immukine, 
Table 2 | Possible Cell Lines for an MHC Class II-related RNAi Screen
Endogenous Type ATCC Reference
MUTZ-3 Human [25]
KG-1 Human CCL-246 [26]
THP-1 Adherent, macrophage-like after stimulation with 
phorbol ester
TIB-202 [27]
LCL Human Epstein Barr virus-transformed Tr a n s f o r m a t i o n 
protocol [28]
MelJuSo Adherent human melanoma cell line [29]
Ectopic Manipulation ATCC Reference
RAW264.7 Adherent murine monocyte/macrophage cell line 
transfected with MHC class II
TIB-71 [30]
Fibroblasts Transfected with MHC class II and Ii [31]
HeLa Transfected with CIITA CCL-2 [32]
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Boehringer Ingelheim)
• Transfection reagent: Fugene 6 (Roche) or alike
• Plasmids: packaging constructs [e.g. pMDLg/
pRRE, pRSV-Rev and pCMV-VSV-G [21]], control 
vectors (e.g. pLKO.1empty, pLKO.1shEGFP, 
pLKO.1shLuciferase, pLKO.1shSCRAMBLE), 
lentiviral plasmid containing shRNA of choice 
(pLKO.1 vectors from Open Biosystems, Thermo 
Scientific, usually 4-5 different sequences per 
gene)
• 0.45 µm filter units (Millipore)
• Polybrene (Millipore) dissolved in PBS
• Ultracentrifugation tubes (Beckman Coulter)
• Ultracentrifuge (Beckman Coulter Rotor SW28)
2.2 Flow Cytometry
• Wash Buffer: PBS containing 2% FCS
• Antibodies: PE anti-human HLA-DR (L243), FITC 
anti-human CD14, FITC anti-human CD83, PE 
anti-human CD80, APC anti-human CD86, APC 
anti-human CD40, APC anti-human DC-SIGN (all 
from BD Biosciences), diluted to 1-10 µg/ml in 
Wash Buffer
• FACS Calibur flow cytometer (BD Biosciences)
2.3 Immunofluorescence
• Cover glasses or µ-Slide 18-well plates (IBIDI)
• Coating: Fibronectin (Invitrogen) diluted to 
20 µg/ml in PBS
• Fixation: PBS with 3,75% formaldehyde (free 
from acid, Merck)
• Permeabilization: PBS with 0.1% Triton X-100 
(Sigma) 
• Blocking: 0.5% bovine serum albumin (BSA, 
Sigma) in PBS
• Primary Antibody (AB): mouse anti-human 
CD63 (or any other late endosomal marker) and 
rabbit anti-HLA-DR [2] diluted in blocking buffer 
• Fluorophore-conjugated Secondary Antibody 
(Invitrogen): diluted in blocking buffer, e.g. 
goat anti-mouse IgG Alexa 488 
• HOECHST 33342 nuclear dye (Invitrogen) 
diluted to 2 µg/ml in secondary AB solution
• Phalloidin-Alexa568 (Molecular Probes) diluted 
to 0.4 U/ml in secondary AB solution
• Mounting medium: Vectashield (Vector 
Laboratories) or 80% glycerol (Merck) in PBS
• AOBS confocal microscope (Leica)
2.4 qRT-PCR
• Roche mRNA Capture Kit (Roche)
• Transcriptor High Fidelity cDNA Synthesis 
Sample Kit (Roche)
• Lightcycler 480 SYBR Green 1 Master (Roche)
• PCR-grade, RNAse-free water: DEPC-treated 
water (Invitrogen)
• Plates (Lightcycler 480 Multiwell 96, Roche)
• 10x primer solution: 3,3 µM of both 
forward and reverse primer in PCR-grade 
water; 18S rRNA reference primers: 
Forward 5’-CGGCTACCACATCCAAGGAA-3’, 
Reverse 5’-GCTGGAATTACCGCGGCT-3’; 
HLA-DR α-chain primers: Forward 
5’-CATGGGCTATCAAAGAAGAAC-3’, Reverse 
5’-CTTGAGCCTCAAAGCTGGC-3’
• PCR machine (Peltier Thermal Cycler, MJ 
Research)
• Light Cycler 480 Detection System (Roche)
2.5 Sample Preparation for Y2H and 
Glutathione-S-transferase(GST) Pulldown
• cDNA clone of gene of interest (e.g. IMAGE 
clone)
• Y2H suitable vector: e.g. pGBT9 (http://www.
dkfz.de/gpcf/y2h.html) 
• Cells of choice for GST pulldown, e.g. 
monocyte-derived imDC or mDC, peripheral 
blood mononuclear cells (PBMC)
• Lysis buffer: 50 mM NaCl (can be up to 500 mM 
to reduce unspecific binding), 50 mM Tris-HCl 
pH 8.0, 10 mM MgCl2, 0.8% NP-40 and protease 
inhibitors (EDTA-free, Roche Diagnostics) in 
water
• Wash buffer: same as lysis buffer, but only 
0.08% NP-40 and without protease inhibitors
• Recombinant GST-tagged protein of choice 
plus free GST for control purposes
• Glutathione Sepharose beads 4G (GE 
Healthcare)
2.6. Coimmunoprecipitation 
• Cell line to be transfected with proteins 
identified to interact (e.g. MelJuSo or 293T) or 
primary immune cell type to study interaction 
of endogenous proteins
• Expression vectors encoding tagged proteins 
of interest (possible tags: GFP, HA, myc etc.)
• NP-40 lysis and wash buffers: see 2.5
• Antibodies: anti-GFP, anti-HA, anti-myc or 
antibodies raised against the proteins of 
interest
• Protein G Sepharose beads 4 Fast Flow (GE 
Healthcare)
2.7 SDS-PAGE and Western Blot
• 2x Sample Buffer: 4 ml distilled water (dH2O), 
10 ml 0.5 M Tris-HCl pH 6.8, 8 ml glycerol, 
16 ml 10% SDS, few flakes of Bromphenol 
blue, store aliquots at -20°C, add 400 µl of 
β-mercaptoethanol per 3,8 ml of sample buffer 
before use.
• Resolving gel buffer: 1.5 M Tris-HCl pH 8.8, store 
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at 4°C
• Stacking gel buffer: 0.5 M Tris-HCl pH 6.8, store 
at 4°C
• 10% sodium dodecylsulphate (SDS) in dH2O
• Acrylamide/Bis-acrylamide: extremely toxic and 
carcinogenic! 40% (ratio 37.5:1, Biorad)
• TEMED (N,N,N,N-Tetramethylethylenediamine, 
Sigma)
• Initiator: 10% ammonium persulphate solution 
(APS) in dH2O, prepare just prior to use
• n-Butanol, water saturated: add dH2O, shake, 
let phases separate, use upper layer
• Electrophoresis buffer: 10x TGS (Biorad), final: 
25 mM Tris, 192 mM glycine, 0.1% SDS, pH 8.3, 
dilute to 1x with dH2O
• Molecular weight standard: Page Ruler 
prestained protein ladder (Thermo Scientific)
• Gel fixative: 40% methanol and 10% acetic acid 
in dH2O
• Silver stain kit: SilverQuest (Invitrogen)
• Transfer buffer: 10x TG (Biorad), final: 25 mM 
Tris, 192 mM glycine, pH 8.3, dilute to 1x with 
dH2O and add 20% methanol
• PVDF membrane (Immobilon-P, Millipore)
• Blotting paper: Whatman (GE Healthcare)
• PBS/T: 0.1% Tween-20 (Sigma) in PBS
• Blocking buffer: 5% skim milk powder in PBS/T
• Primary AB: diluted in 1% blocking buffer
• Secondary AB: e.g. swine anti-rabbit IgG horse 
radish peroxidase-conjugated (Dako), diluted 
1:5 000 in 1% blocking buffer
• Detection: Amersham ECL Detection Reagents 
(GE Healthcare)
• Biorad Mini Protean and Transfer System
3. Methods
3.1 Lentivirus Production
• 293T cells are grown in 150 cm2 flasks in DMEM 
supplemented with 10% FCS.
• Cells are washed with PBS, trypsinized and 
seeded at 3.5 x 106 per 10 cm tissue culture 
dish. Per lentiviral shRNA construct four dishes 
are required.
• After 24 h cells are transfected. The three 
packaging constructs are mixed 1:1:1. The ratio 
of this packaging trio to shRNA construct 
(pLKO.1) is 1:1. To 1.4 ml of serum-free DMEM 
(room temperature) add 56 µl of Fugene 6. In a 
separate tube (see Note 1) mix 7 µg (see Note 2) 
of packaging vectors with 7 µg of pLKO.1shRNA. 
Combine Fugene/DMEM and DNA, incubate 
for 30 min at room temperature. Replace the 
medium in the 10 cm dishes with 12.6 ml of 
DMEM/FCS. Add DNA/Fugene dropwise.
• After 24 h change medium to 8 ml Cellgro. The 
cells should be 50% confluent. Handle them 
Figure 1 | Redistribution of MHC Class II after 
Candidate Gene Silencing
While MHC class II colocalises with the late endosomal 
marker CD63 on intracellular vesicles in immature 
DC (imDC, upper panel), most of MHC class II resides 
at the plasma membrane (PM) in mature DC (mDC, 
lower panel). When factors negatively influencing this 
transport process are silenced MHC class II molecules 
are redistributed to the PM, which resembles the 
phenotype of an mDC, while other maturation markers 
remain negative as is typical for an imDC (determined 
by flow cytometry). DC are fixed and stained with 
antibodies against CD63 and MHC class II. Fluorophore-
conjugated secondary antibodies are used to visualize 
the localization of the two molecules by confocal 
microscopy. Bar = 10 µm.
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carefully as they detach very easily.
• After another 24 h harvest the supernatant. 
Filter through a 0.45 µm filter. Concentrate the 
viral supernatant 100x by ultracentrifugation 
at 20.000 x g at room temperature for 2 h. 
Resuspend the viral pellet in 360 µl Cellgro 
(see Note 3) and snap freeze in liquid nitrogen. 
Store at -80 (see Note 4). The viral suspension 
obtained is enough to perform transduction of 
at least three different monocyte donors.
•  Add another 7 ml of Cellgro to the 293T cells. A 
second harvest can be performed the day after. 
3.2 Silencing Candidate Genes in DC
Human monocytes are transduced with lentivirus 
carrying shRNA constructs targeting the selected 
candidate genes followed by differentiation into 
imDC. Several control vectors should be used. An 
average of their phenotype serves as a reference 
point. The experiment should be performed in several 
donors as a big difference between individuals is 
usually observed when working with primary cells. 
General effects can be easily separated from MHC 
class II-specific ones by including additional cell 
surface markers such as MHC class I (for effects on 
the entire MHC locus), CD63 (for effects on recycling 
between PM and late endosomes) and transferrin 
receptor (for recycling in early endosomes). 
• Thaw frozen monocytes. Wash 2x with Cellgro. 
Plate cells at 1 x 106 in 12-well plate in 900 µl 
Cellgro supplemented with IL-4 (800 U/ml 
final concentration), GM-CSF (1000 U/ml) and 
Polybrene (4 µg/ml). Add 100 µl of 100x viral 
supernatant.
• After 24 h remove 400 µl of medium and refresh 
with 1.4 ml of Cellgro/IL-4/GM-CSF. 
• On day 5 mature a well of untreated imDC with 
LPS (2.5 µg/ml) and IFN-γ (1000 U/ml) to use as 
an mDC control.
• After 24 h determine the cell surface levels of 
MHC class II and other maturation markers 
by flow cytometry and the intracellular MHC 
class II distribution by immunofluorescence. To 
ensure that imDC were successfully generated 
monitor the reduction of CD14 and the increase 
of DC-SIGN cell surface levels compared to 
monocytes by flow cytometry. Furthermore, 
the cells are subjected to qRT-PCR to establish 
the level of knockdown and to rule out any 
effects on MHC class II gene transcription.
3.3 Phenotyping DC by Flow Cytometry
DC are semi-adherent and can be detached by 
repetitive pipetting and flushing the well.
• Approx. 50% of cells remain after differentiation 
from monocytes to imDC. Transfer approx. 
100 000 DC per staining to a round-bottom 
96-well plate. Spin cells down and discard 
supernatant. Wash cells one time with buffer 
and spin down.
• Add 20 µl of antibody cocktail (e.g. FITC-CD83, 
PE-MHCII, APC-CD40) and incubate for 30 min 
on ice in the dark. Wash cells with buffer 
followed by centrifugation.
• Resuspend pellet in 100 µl of wash buffer. 
Measure the cell surface expression of the 
respective markers using a plate reader 
attached to the flow cytometer.
3.4 Intracellular MHC Class II Distribution
In imDC MHC class II mainly resides in late endosomes 
where it colocalizes with CD63. When exposed to 
danger signals DC undergo striking morphological 
changes one of which is a redistribution of MHC class 
II to the plasma membrane. To determine whether 
any of the silenced candidate genes is responsible 
for maintaining MHC class II’s endosomal location 
the colocalisation between CD63 and MHC class II is 
being determined (Figure 1).
• Coat µ-slides for 30 min at 37°C with fibronectin 
and rinse with PBS.
• Add 30 µl DC suspension and incubate in a wet 
chamber at 37°C for 6-7 h. All the following 
steps are carried out at room temperature.
• Fix cells with 3.75% formaldehyde for 15 min and 
wash by immersing the slide in a chamber filled 
with PBS. Slides may be stored for several days 
in PBS at 4°C.
• Permeabilize the cells with Triton-X for 10 min 
and wash with PBS.
• Unspecific binding is prevented by blocking 
with 0.5% BSA solution for 45 min.
• Add the primary antibody solution and incubate 
for 60 min. 15 µl of solution are enough to cover 
the entire surface area of one well.
• Wash the slides 3x for 5 min by placing the PBS-
filled chamber on a shaking platform.
• Add the secondary antibody solution containing 
HOECHST as a nuclear dye and phalloidin to 
stain the actin cytoskeleton and incubate for 
30 min in the dark.
• Wash the slides again 3x for 5 min and fill 
each well with 80% glycerol. The slides can be 
stored at 4°C for a few days until analysis with 
a confocal microscope. When using individual 
cover glasses perform all washing steps in 
74
multi-well plates and mount the glasses in the 
end using a drop of mounting medium on a 
glass slide. Remove excess mounting medium 
by pressing the glass slide on tissue. 
• Analyze the MHC class II distribution in DC by 
confocal microscopy.
3.2 Determination of mRNA Levels in DC 
by qRT-PCR 
This method is used to determine the knockdown 
efficiency on one hand and to rule out any effects 
on transcriptional regulation of MHC class II on the 
other hand (see Note 5).
• Wash 50 000 DC 2x with cold PBS (see Note 6) 
and lyse in 50 µl lysis buffer (see Note 7). 
• Add 4 µl of biotinylated oligo dT primer and 
anneal for 5 min at 37°C. Transfer lysate to 
a streptavidin-coated tube and incubate for 
another 5 min at 37°C (see Note 8).
• Add 200 µl of wash buffer and discard. Repeat 
washing step 3x. Leave the liquid of the last 
wash in the tube while preparing the cDNA 
synthesis master mix.
• Per reaction you will need: 6 µl 5x Reaction 
Buffer, 20 µl RNAse-free water, 0.5 µl RNAse 
Inhibitor, 2 µl nucleotides (dNTPs), 1 µl DTT, and 
0.5 µl Reverse Transcriptase.
• Discard wash buffer completely. When 
pipetting away the liquid avoid touching the 
walls of the tube as this might destroy the layer 
of streptavidin. Add 30 µl of master mix.
• Reverse transcribe the captured mRNA into 
cDNA with a PCR program of 30 min 50°C 
and 5 min 85°C. Stop at 99°C. At such high 
temperature the bond between biotin and 
streptavidin is broken and the cDNA can be 
removed.
• Quickly remove the 30 µl of liquid and replace 
them with 50 µl of PCR-grade water. Incubate 
for 3 min at 99°C. Remove the liquid and 
combine it with the previous 30 µl. The cDNA 
can be stored at -20°C.
• For the qRT-PCR reaction 96-well plates are 
used. Per well add 5 µl of SYBR Green, 1 µl of 
10x primer solution (3.3 µM each) and 1.5 µl of 
water. Add 2.5 µl of cDNA. Seal the plate and 
spin it to collect all fluid at the bottom of each 
well. 
• Insert the plate in the LightCycler and start the 
run, which will take about 1 h 20 min.
• Analyze using the comparative CT method 
(DDCT). Relate the results to the 18S rRNA 
values and normalize it to the average of 
control shRNA-treated cells.
3.3 Identification of Interaction Partners/
Effectors by Y2H 
• The Y2H analysis can be outsourced (e.g. http://
www.dkfz.de/gpcf/y2h.html). Alternatively, a 
protocol on how to perform Y2H can be found 
here [22].
• To prepare the sample for Y2H clone the cDNA 
of your gene of interest into a Y2H-combatible 
vector.
• Choose an appropriate cDNA library to screen 
(e.g. lymph node). Choose a cell type/tissue 
where your gene of interest is expressed under 
normal conditions. Information about tissue 
distribution can be found at http://biogps.org 
[23].
3.4 Identification of interaction partners/
effectors by GST pulldown
• To prepare a protein for GST pulldown clone 
the cDNA of your gene of interest into a GST 
expression vector. Produce the recombinant 
GST-tagged protein as well as free GST in e.g. 
Escherichia coli and purify them.
• Wash 120 µl of glutathione beads 3x in lysis 
buffer. Spin at 500 x g for 3 min. Remove liquid 
carefully (see Note 9). 
• Couple 50 µg of recombinant protein 
dissolved in lysis buffer to the beads for 1 h. All 
subsequent incubation steps are performed at 
4°C on a spinning wheel. Wash beads 3x in lysis 
buffer (see Note 10).  
• Lyse 200 x 106 PBMC [cell number may vary 
depending on (1) the expression level of the 
protein of interest and (2) the availability of the 
cell type you want to use] in 750 µl lysis buffer 
for 30 min. Centrifuge for 10 min at maximum 
speed.
• Incubate beads with the supernatant of lysed 
cells for 1 h or overnight. Wash 1x in lysis buffer 
and 3x in wash buffer (see Note 10). 
• Remove all liquid (see Note 9). Add 25 or 50 µl 
of 1x sample buffer (prepare by mixing equal 
volumes of water and 2x sample buffer), boil 
for 5 min at 100°C, centrifuge at max. speed 
and load supernatant on one or two gels, 
respectively.
3.5 SDS-PAGE and Mass Spectrometry
• Wash glass plates, clean with 70% ethanol and 
dry.
• Prepare two 1 mm 12% resolving gels by mixing 
4.35 ml water with 2.5 ml resolving gel buffer, 
0.1 ml 10% SDS solution and 3 ml acrylamide/bis-
acrylamide solution. Start the polymerization 
by adding 50 µl of 10% APS solution and 5 µl 
of TEMED. Pour the gel leaving space for the 
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stacking gel. Overlay with n-butanol.
• After polymerization is complete pour away the 
butanol and rinse the gel with water. Absorb 
residual water using blotting paper.
• Prepare 4% stacking gel mixing 3.22 ml water 
with 1.25 ml stacking gel buffer and 50 µl 
10% SDS solution and 0.5 ml acrylamide/bis-
acrylamide solution. Start the polymerization 
by adding 25 µl of 10% APS solution and 5 µl of 
TEMED. Pour the liquid on top of the resolving 
gel and insert the comb.
• When polymerization is complete, assemble 
the gel unit, remove the combs, fill the unit 
with 1x electrophoresis buffer and flush each 
sample well using a long slender tip or syringe 
with needle.
• Load samples. Fill empty wells with 1x sample 
buffer. Include a weight marker in one lane.
• Close the unit and connect it to a power supply. 
Set the power supply to constant voltage and 
run at 90 V. When the sample front has passed 
the stacking gel the voltage may be increased 
to 110 V. 
• When the SDS-PAGE run is finished, remove 
the gel and fix it for at least 20 min before 
proceeding to the silver staining.
• Perform mass spectrometric analysis to 
determine the proteins that have interacted 
with your protein of choice, but not with GST 
alone (see Note 11).
3.6 Confirmation of Interaction by 
Coimmunoprecipitation 
Interactions identified by Y2H or GST pulldown need 
to be confirmed. If antibodies are available it is 
better to perform the coimmunoprecipitation (CoIP) 
with endogenous proteins in e.g. imDC or mDC. If 
such antibodies are not available ectopic expression 
of the proteins of interest in a cell line may be 
applied. By tagging the proteins with two different 
tags interactions can be studied. 
• For CoIP either isolate the cell type of choice 
to confirm the interaction or transfect a cell 
line with plasmids encoding tagged versions 
of the two putative interaction partners. Use 
e.g. Fugene 6 for the transfection following the 
steps described under 3.1.
• Wash 50 µl of protein G beads 3x in lysis 
buffer. Spin at 500 x g for 3 min. Remove liquid 
carefully (see Note 9). 
• Couple 5 µl (the amount might be reduced to 
as little as 1 µl depending on the strength of 
the antibody) of antibody (against interaction 
partner one or against the tag of interaction 
partner one) diluted in lysis buffer to the beads 
for 1 h. All subsequent incubation steps are 
performed at 4°C on a spinning wheel. Wash 
beads 3x (see Note 10).  
• Lyse 5 x 106 transiently transfected cells (more 
primary cells are necessary when detecting 
endogenous proteins) in 750 µl lysis buffer 
for 30 min. Centrifuge for 10 min at maximum 
speed.
• Mix 50 µl of supernatant with an equal volume 
of 2x sample buffer, boil for 5 min at 100°C, 
centrifuge and store at -20°C. Load on a gel as a 
total lysate control.
• Incubate beads with the remaining supernatant 
of lysed cells for 1 h or overnight. Wash 1x in 
lysis buffer and 3x in wash buffer (see Note 10). 
• Remove all liquid (see Note 9). Add 25 of 1x 
sample buffer (prepare by mixing equal volumes 
of water and 2x sample buffer), boil for 5 min at 
100°C, centrifuge and load supernatant on a gel.
• Perform SDS-PAGE as described under 3.5. 
• Prepare pieces of blotting paper and PVDF 
membrane slightly larger than the gel and soak 
the membrane in 100% methanol for 2-3 min.
• Fill a tray with 1x transfer buffer. Submerge 
the transfer cassette. Stack a foam pad and 
three pieces of blotting paper on the dark 
plastic side of the cassette. Remove the gel 
from the electrophoresis chamber, rinse with 
water, and place onto the filter paper. Place the 
membrane on the gel (avoid the introduction 
of bubbles. Add three pieces of blotting paper 
prewet in transfer buffer. Remove any bubbles 
in between the different layers by rolling a 
serological pipette over the stack. Place wet 
foam pad on top and close the cassette.
• Insert the cassette into the transfer tank. Black 
side of the cassette facing the black side of 
the tank. Double check that the membrane 
is placed between the gel and the anode (+). 
Proteins will migrate towards the anode. If 
inserted the opposite way proteins will be lost 
in the buffer.
• Place an ice block in the transfer tank and fill 
the tank with 1x transfer buffer. Add a magnetic 
stirrer. 
• Place tank on a stirrer platform, close lid and 
perform transfer at constant current of 150 mA 
for 1.5 h. Alternatively, the transfer can be 
performed at constant 20 mA in the cold room 
overnight.
• Remove the PVDF membrane from the transfer 
unit (see Note 12). The prestained molecular 
weight marker should be clearly visible.
• Block the membrane in 10 ml of milk solution 
for 1 h at room temperature (RT) rocking on a 
shaking platform. Wash the membrane 3x with 
PBS/T for 5 min.
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• Add the primary antibody solution (against 
interaction partner two or tag of interaction 
partner two) and incubate for at least one hour 
at RT or overnight at 4°C. Wash the membrane 
3x with PBS/T for 5 min.
• Add the secondary antibody solution and 
incubate for 1 h at RT. Wash the membrane 3x 
with PBS/T for 10 min.
• Prepare the ECL reagents by mixing equal 
volumes of the two components. Remove the 
membrane from the washing solution. Remove 
excess buffer by blotting one corner of the 
membrane on tissue. Place membrane on clear 
plastic foil, cover with ECL mix and wrap in foil. 
Ensure complete coverage of the membrane 
by striking the liquid from one side to the other 
repeatedly. 
• After 1 min remove excess liquid and wrap 
membrane in clean foil. Place membrane in a 
film cassette.
• In a dark room expose X-ray film to the 
chemiluminescence signals and develop 
afterwards. The exposure time needs to be 
adjusted to the signal strength.
3.7 Colocalisation Studies on 
putative Interaction Partners using 
Immunofluorescence Microscopy
Colocalisation observed by immunofluorescence (IF) 
represents an alternative method to support protein 
interaction data.
• Prepare primary cells as described under 3.4 or 
transiently transfected cells as described under 
3.6.
• Determine the localization of the two putatively 
interacting proteins by staining them with 
antibodies directly or indirectly (anti-tag). See 
3.4 for procedure.
• To place these interactions in context with 
MHC class II transport stain also for MHC class 
II or for the compartments involved in MHC 
class II antigen presentation (e.g. CD63 for 
late endosomes). Phalloidin is a stain for the 
actin cytoskeleton and will help to determine 
whether transport occurs along actin filaments. 
Furthermore, the microtubule network may be 
visualized using anti-tubulin antibodies.
3.8 Conclusion
An RNAi screen often results in a list of genes that 
are somehow affecting a biological process. To 
classify these ‘hits’ HT follow-up screens are needed. 
When all these individual datasets are integrated 
and stringent criteria are set a list of candidates 
emerges that might play a role in e.g. the control 
of MHC class II transport. To study and confirm 
these candidates experiments in primary immune 
cells (DC) need to be performed. Silencing can be 
achieved by introduction of shRNA constructs using 
lentivirus transduction. Changes in cell surface levels 
of MHC class II and its intracellular distribution are 
measured. To extend the findings of individual new 
players to whole pathways interaction partners 
and effectors can be identified using Y2H and 
proteomic approaches. All new findings require 
further confirmation applying alternative methods. 
Including appropriate controls ensures that the new 
findings are MHC class II-specific and do not affect 
any general transport or protein secretion pathway.
4. Notes
1. All tubes should be made from polyethylene to 
limit the rate of liposomes sticking to the tube’s 
wall.
2. In order to monitor the transfection efficiency 
0.5 µg of pEGFPC1 (Clontech) may be added to 
the packaging vector mixture. The amount of 
pLKO.1shRNA construct should be reduced to 
6.5 µg respectively. More than 90% of 293T cells 
should be GFP-positive after 48 h. 
3. Add Cellgro to pellet and leave it standing for 
a few minutes before pipetting up and down 
gently (try not to introduce bubbles).
4. To be able to set a certain mode of infection 
(MOI) the viral titer of your lentivirus 
preparation needs to be determined as 
transducing units per ml (TU/ml). Produce GFP-
expressing lentiviral particles by introducing the 
pLKO.1TURBOGFP construct. Infect monocytes 
with decreasing volume of virus supernatant 
and determine the amount of GFP-positive 
colonies by microscopy after 48 h. Multiply this 
number with the dilution factor.
5. A useful program to design primers against 
your gene of interest for qRT-PCR is Perlprimer 
[24]. Adjust the settings according to what 
is being recommended with the SYBR Green 
you are using. BLAST the primer sequences to 
ensure they only recognize one gene. 
6. To ensure RNAse-free working conditions wipe 
surfaces and tools with 70% ethanol. Use filter 
tips and RNAse-free tubes and reagents. Avoid 
working in a laminar flow hood as the flow of 
air will favor contamination with RNAses.
7. The solution is very viscous. One freeze-thaw 
cycle at -80°C helps to complete the lysis.
8. When working with the SA-coated tubes avoid 
the introduction of bubbles and scratching the 
wall of the tubes while pipetting!
9. Use a needle of diameter 0.4 mm. Liquid can be 
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entirely removed without loss of beads.
10. Transfer beads to a fresh tube during the last 
washing step. This will help eliminate proteins 
that unspecifically stick to the tube’s wall.
11. Contamination of gels with keratine can cause 
problems during mass spectrometry. To ensure 
keratine-free conditions pre-cast gels can be 
used.
12. Use forceps to handle the membrane. The 
transfer of the prestained marker to the 
membrane gives an indication of the quality of 
protein transfer. To get an overview of protein 
transfer across the entire membrane stain with 
Ponceau S for a few minutes. Destain by rinsing 
with excess of water.
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sequences can be easily introduced into cells by 
lipid-based transfection methods. Libraries of siRNA 
are often designed in an arrayed format with every 
well of a 96- or 384-well plate containing siRNAs 
targeting a single gene only. This naturally leads to a 
larger format; hence, automated liquid handling and 
high throughput analysis equipment are required. 
An siRNA species called enzymatically generated 
siRNA (esiRNA) can be easily produced by the 
researcher himself. For an overview of advantages 
and disadvantages of the various setups see [6].
Depending on the RNA format, the analysis assay 
might have to be performed in a high throughput 
manner. Robustness is a necessity. Various 
normalization procedures have been described 
[7, 8]. The cutoff levels are arbitrarily chosen and 
in turn influence the rate of false-positive and 
-negative candidates. Validation steps need to be 
applied to obtain a list of more reliable candidates. 
Again these have to be carefully chosen. Various 
reviews are available, which highlight tips, tricks and 
pitfalls for RNAi screening [6, 9, 10]. The take-home 
message is; clever design is crucial. By choosing 
proper controls one can get an idea of the ‘screening 
window’ (the maximum changes expected for a 
certain read-out), which will ultimately determine 
the robustness of the entire screen. A common 
normalization method is the so-called z-score [11], 
which is mainly dependent on the standard deviation 
of the control samples. The primary screen is often 
followed by one or several follow-up screens aiming 
at candidate validation. Furthermore, these screens 
may provide additional information about the 
candidate genes, which may become useful when 
plotting interaction networks. While other groups 
have established screening regimes suitable for the 
scientific questions they addressed [12-15], we have 
come up with a unique multi-dimensional approach 
that integrated various data sets to arrive at a more 
complete understanding of a crucial cellular process 
– MHC class II antigen presentation (described in 
Chapter 1 and 2 of this thesis).
Whenever an RNAi screen is set up one has to be 
aware of its strengths as well as its limitations. 
In our approach we ensured robustness using a 
melanoma cell line, which possesses a complete 
and functional MHC class II antigen presentation 
machinery [16]. A cell line facilitates reproducible 
transfection efficiency over long periods of time. 
There is virtually no limit in resources as opposed 
to primary cells (which would show donor to donor 
variation, thus affecting the statistical power of 
the assay). Two monoclonal antibodies were used 
to detect MHC class II on the cell surface in two 
different states, hence distinguishing target genes 
Summary & Discussion
Major histocompatibility class II molecules (MHC 
class II) are one of the key regulators of adaptive 
immunity because of their specific expression 
by professional antigen presenting cells (APC). 
They present peptides derived from endocytosed 
material to T helper lymphocytes. Consequently, 
MHC class II is fundamental in orchestrating 
both cellular and humoral immune responses. A 
genetic association of certain MHC class II alleles 
with autoimmunity has long been established. 
The molecular mechanisms underlying this 
association are only poorly understood. An in depth 
understanding of the antigen presentation pathway 
by MHC class II is essential for the improvement of 
current therapies.  General aspects of MHC class II 
antigen presentation and ways to manipulate it have 
been widely discussed in the Introduction Chapter 
and Chapter 3. Here, the tools to arrive at a systems 
understanding of MHC class II antigen presentation 
will be discussed. What are the advantages and 
disadvantages of a genome-wide screen? And how 
can a multi-dimensional, data-integrating approach 
increase the understanding of the systems biology 
of MHC class II? 
In 2006, the Nobel Prize in Medicine was awarded 
to Andrew Fire and Craig Mello for their work on 
RNAinterference (RNAi) in C. elegans [1]. RNAi 
occurs in many eukaryotic organisms and is thought 
to be an antiviral mechanism triggered by double 
stranded (ds)RNA, which leads to sequence-specific 
mRNA degradation. Endogenously encoded micro 
(mi)RNA molecules target the 3’ untranslated region 
(UTR) of mRNA and are involved in gene regulation. 
Nowadays, RNAi is applied in mammalian cells as 
means to silence the expression of genes of interest.
As early as 2004, first efforts had been undertaken 
to perform genome-wide RNAi screens [2-4]. And 
this was just the beginning. Ever since its discovery, 
RNAi has been applied many a times to study signal 
transduction, cancer biology and host-pathogen 
interactions, to just name a few of the biological 
processes addressed (reviewed in [5]). The setup of 
these screens including the analysis methodology, 
however, varied greatly.
Different species of RNA can be used. Short hairpin 
RNA (shRNA) is often delivered by viral transduction, 
which has the advantage of stable integration in 
the genome and expression of selection markers. 
Libraries of shRNA are often provided in pools 
of several thousand different sequences, which 
makes it a more economic approach. Another very 
popular format is small interfering RNA (siRNA). 
These chemically synthesized 19-27 nucleotide long 
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involved in the regulation of overall surface levels 
and/or peptide loading. We have integrated these 
primary results with information on the intracellular 
distribution of MHC class II gathered in a secondary 
microscopy-based assay. Microscopy in combination 
with automated image analysis opens new venues 
to study complex cellular processes, such as 
intracellular trafficking [17], which are of great 
importance in MHC class II antigen presentation. It 
will certainly be further exploited in the near future, 
as high-resolution (semi)-automated microscopes 
and the corresponding image software undergo 
constant improvement.
MHC class II is selectively expressed on a subset 
of immune cells. Most of the genes discovered in 
our screen are affecting MHC class II expression 
at the cell surface when silenced. Therefore, they 
should contain those candidates that control 
tissue-specific MHC class II gene expression. The 
networks controlling these factors are unknown. 
We used our RNAi screen results to address this 
issue and unravel general cell biological terms 
defining tissue-selective expression of MHC class 
II. Therefore, high-throughput quantitative PCR 
was performed to investigate effects of gene 
silencing on the expression of the MHC class II 
locus. From this screen we were able to deduct a 
complex feedback regulated network of signaling 
molecules and transcription factors, which in turn 
regulate the levels of CIITA – the master regulator 
of MHC class II transcription. Further bioinformatics 
investigation revealed general cell biological cues 
such as signaling and chromatin modifications as 
modifiers of tissue-selective expression of MHC class 
II. Using RNAi to unravel transcriptional networks is 
being acknowledged as a powerful tool to uncover 
regulatory interactions that modulate transcription 
factor activity [18].
In general, the introduction of bias of any kind 
was prevented as much as possible by always 
investigating the list of candidates as a whole. We 
have subjected them to multiple assays, which we 
finally integrated to obtain networks of similarity 
in phenotype. To ensure that we are not studying 
artifacts due to the use of a melanoma cell line, we 
have additionally determined the expression levels 
of all genes in a panel of human primary immune 
cells. Only those candidates expressed in immune 
cells were considered for further studies.
Nevertheless, false-positive or -negative candidates 
can never be entirely excluded, without losing too 
many ‘real hits’. Any screening setup has limitations 
which need to be taken into account. One major 
issue is the variability of knockdown efficiency 
achieved by different siRNA pools. The transfection 
method has been optimized beforehand targeting 
a few representative genes, but it will never be 
optimal for all. Often lethality caused by silencing 
particular genes (such as PLK1) can be observed and 
this has to be corrected for. Usually an arbitrary cut-
off is chosen, and conditions of too low cell viability 
are excluded from the analysis. Despite the fact that 
the melanoma cell line MelJuSo has been shown to 
be properly presenting peptides bound to MHC class 
II [16] artifacts due to these cells’ origin can never be 
entirely excluded. Hence, a thorough confirmation 
of selected candidates in primary APC has to be 
executed.
Dendritic cells (DC) have first been described in 
the 1970s [19], a discovery which has recently been 
awarded the Nobel Prize in Medicine for Ralph 
Steinman. DC are the main professional APC in our 
body. Starting in the early 1990s, culture methods 
have been described to obtain DC from bone marrow 
precursors or peripheral blood monocytes. Again 
these findings were pioneered by Ralph Steinman 
together with Kayo Inaba [20, 21]. 
We have used our integrated data sets (cell surface 
as well as intracellular MHC class II localization, 
expression in immune cells, and effects on MHC 
class II locus transcription) to select candidates 
that we think are involved in orchestrating the 
redistribution of MHC class II from intracellular late 
endosomal structures to the plasma membrane 
during DC activation (maturation). Establishing 
a lentiviral transduction method for delivery of 
shRNA constructs into monocytes that are then 
differentiated into immature DC enabled us to study 
the function of the selected candidates in human 
primary immune cells (described in Chapter 4 of this 
thesis). One striking finding was that the small GTPase 
ARL14 (sometimes referred to as ARF7) seems to be 
a negative regulator of outward transport of MHC 
class II. When silenced in immature DC, the majority 
of MHC class II molecules are redistributed to the 
plasma membrane leaving late endosome void of 
MHC class II. While those ARL14-silenced cells remain 
immature in terms of other activation markers they 
strikingly resemble a mature DC in regards to their 
MHC class II localization (see Chapter 1 and 2 of this 
thesis). This is a unique observation. By silencing 
one gene we have uncoupled two processes that 
were hitherto coupled: export of MHC class II and 
maturation of DC.  
We then set out to unravel the mechanism 
underlying the MHC class II transport regulation 
by ARL14. Through a series of proteomic assays we 
have established various interaction partners, one of 
which is a so far unknown protein, now named ARF7 
effector protein (ARF7EP). We propose that ARL14 is 
recruited to late endosomes by its guanine exchange 
factor PSD4, which binds to specific lipids on late 
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endosomes through its pleckstrin homology domain. 
ARL14 is linked to the actin cytoskeleton via ARF7EP 
and the motor myosin 1E. This complex seems to 
orchestrate the positioning of MHC class II-positive 
late endosomal vesicles along the cytoskeleton (see 
Chapter 1 and 2 of this thesis). 
Other members of the ARF-like family of GTPases 
have recently been found to be implicated in 
lysosomal trafficking [22]. Lysosome-associated 
ARL8B was shown to regulate endosome to lysosome 
traffic of various cargos. It directly recruits, VPS41, a 
subunit of the HOPS (homotypic fusion and protein 
sorting) complex. The HOPS complex has been well 
described in yeast, where it is involved in trafficking 
to the vacuole, an organelle similar to the lysosome 
[23]. The described function of ARL8B does not 
seem to be mediated by any of the known effectors 
of late endosome (LE) to lysosome trafficking. These 
are the small GTPase RAB7, RILP (RAB7 interacting 
lysosomal protein) [24], the cholesterol sensor 
ORP1L and the ER-resident protein VAP [25]. Lately, 
this machinery has been linked to the HOPS complex 
too. RILP seems to act as a bridge between two LE 
decorated with the RAB7/RILP/HOPS complex [Rik 
van der Kant, personal communication]. While the 
GTPase ARL14 is involved in positioning LE along the 
actin cytoskeleton, the GTPases ARL8B, RAB7 and 
possibly others seem to control late endosome and 
lysosome vesicle tethering and fusion.
RNAi screening will become a more and more 
affordable and feasible tool for the understanding 
of molecular processes in immune cells as the 
development of high-throughput techniques and 
automated analysis software progresses [26]. 
Studying the MHC class II pathway on a genome-wide 
scale opens up many opportunities of manipulation 
(see Chapter 3 in this thesis). Understanding antigen 
presentation in more detail will ultimately lead to 
new strategies of inhibiting unwanted immune 
responses (e.g. in autoimmune diseases) as well 
as boosting immunity (e.g. in cancer or vaccine 
development). 
Yet, defining novel factors using the new 
technologies described in this thesis (Chapters 1, 2 
and 4) should be considered as a basis for a deeper 
understanding of biology, which still requires much 
and hard work. The findings presented here may be 
further supported by the large data sets that appear 
in the public domain. We believe that an integration 
of wet-lab and computer-based biology will guide 
future cell biology and immunology to a deep 
understanding of important biological processes 
and to new ways to manipulate these in disease. 
Manipulating MHC class II may be of relevance for 
auto-immune diseases, transplantation as well as 
vaccination strategies and I hope that my work may 
provide a basis for novel insights and improvement.
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Nederlandse samenvatting
Major Histocompatibility Complex klasse II moleculen 
(MHC klasse II) zijn belangrijke regulatoren van de 
adaptieve immuun respons. Ze komen specifiek tot 
expressie in professioneel antigen presenterende 
cellen (APC) waar ze peptiden, afkomstig van 
opgenomen materiaal, presenteren aan T helper 
lymphocyten. MHC klasse II is fundamenteel voor 
het dirigeren van zowel de cellulaire als de humorale 
immuun respons.
Sinds lange tijd is bekend dat er een genetisch 
verband bestaat tussen bepaalde MHC klasse II 
allelen en bepaalde auto-immuunziekten, maar tot 
nu toe is er nog geen goede verklaring voor het 
moleculaire mechanisme achter dit verband. Meer 
kennis over MHC klasse II antigeen presentatie is 
essentieel om de huidige behandelmethodes voor 
auto-immuunziekten te verbeteren.
Wij hebben een unieke methode ontwikkeld waarin 
verschillende datasets met elkaar zijn geïntegreerd 
om een compleet beeld te krijgen van dit belangrijke 
cellulaire proces, MHC klasse II antigeen presentatie 
(zie hoofdstuk 1 en 2 van dit proefschrift).
Bij het opzetten van een RNAi screen is het 
belangrijk de voordelen, maar ook de nadelen van de 
techniek te kennen. In onze aanpak hebben we voor 
robuustheid gezorgd door gebruik te maken van een 
melanoma cel lijn, welke een functionele MHC klasse 
II antigeen presentatie route bezit. Door gebruik te 
maken van twee monoclonale antilichamen konden 
we onderscheid maken tussen twee verschillende 
vormen van MHC klasse II aan de cel oppervlakte. Dit 
gaf ons de mogelijkheid genen te identificeren die 
betrokken zijn bij de regulatie van ofwel de totale 
MHC klasse II levels ofwel de peptide belading van 
MHC klasse II aan het cel oppervlak. Deze gegevens 
hebben we geïntegreerd met gegevens uit een 
tweede screen, in welke we gekeken hebben naar de 
lokalisatie van intracellulaire MHC klasse II moleculen 
met behulp van confocale microscopie. Daarnaast 
hebben we ook op grote schaal door middel van 
kwantitatieve PCR gekeken naar het effect van 
gen onderdrukken op de expressie niveaus van de 
MHC klasse II locus. Met behulp van de data die 
deze screen opleverde, konden we een complex 
CIITA regulerend netwerk tekenen, bestaande 
uit signaalmoleculen en transcriptiefactoren, 
met vele feedbackloops. CIITA is de belangrijkste 
regulator van MHC klasse II transcriptie. 
Door geen voorselectie te maken, maar telkens de 
gehele lijst met kandidaat genen te gebruiken voor 
follow-up experimenten, hebben we uiteindelijk een 
unbiased dataset verkregen. De kandidaat genen 
zijn onderworpen aan verschillende testen/screens. 
Door de verschillende resultaten te integreren 
hebben we deze kandidaat genen kunnen clusteren 
naar gelijkende effecten op de MHC klasse II 
antigeen presentatie route. 
Deze geïntegreerde dataset is gebruikt om kandidaat 
genen te selecteren die naar onze mening betrokken 
zijn bij het dirigeren van MHC klasse II moleculen 
van intracellulaire laat endosomale membranen 
naar het plasma membraan tijdens dentritische cel 
(DC) activatie (maturatie). Voor een aantal van deze 
genen hebben we de betrokkenheid bij dit proces 
kunnen bevestigen. Eén van deze genen, ARL14 
hebben we in meer detail bestudeerd. Met behulp 
van proteomics hebben we interactiepartners 
van ARL14 geïdentificeerd. Dit ARL14 complex lijkt 
belangrijk te zijn voor de lokalisatie van MHC klasse 
II positieve laat endosomale vesicles langs het 
cytoskelet (zie hoofdstuk 1 en 2 van dit proefschrift).
Het beter begrijpen van de systeembiologie van 
MHC klasse II presentatie is slechts één manier om 
nieuwe targets te vinden voor de behandeling van 
bijvoorbeeld auto-immuunziekten. De afgelopen 
tien jaar zijn verschillende methodes beschreven 
waarop de presentatie van antigeen door MHC 
klasse II gemoduleerd kan worden. Deze zijn 
uitgelicht in hoofdstuk 3 van dit proefschrift.
DCs hebben een grote bijdrage in immuun regulatie 
en antigeen presentatie. Daarom komt er bij het 
bestuderen van MHC klasse II moleculen altijd 
een moment waarop DCs een rol gaan spelen. In 
hoofdstuk 4 van dit proefschrift worden methoden 
beschreven die de onderzoeker in staat stellen de 
MHC klasse II route te bestuderen in dit professionele 
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